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Dissertation supervised by Paula A. Witt-Enderby 
 Tamoxifen is a first-generation selective estrogen receptor modulator, which reduces the 
risk of both invasive and non-invasive breast cancer (BC) as well as tumor recurrence in several 
clinical trials. However, chronic use of tamoxifen can increase uterine cancer risk and induce 
tamoxifen resistance. In past studies, melatonin alone reversed tamoxifen resistance induced by 
light exposure at night in rodents. This study demonstrates that melatonin or melatonin-based 
ligands (e.g., melatonin-tamoxifen drug conjugates) may be novel BC therapies that are efficacious 
and free of side effects. To investigate this further, five melatonin-tamoxifen drug conjugates with 
different linker sizes were synthesized and screened for their anti-cancer actions in a variety of BC 
cells that included: MCF-7 (ER+), tamoxifen-resistant MCF-7 (TamR), MMC (HER2+), MDA-
MB-231 (triple-negative), and BT-549 (triple-negative). Specifically, their actions against cell 
viability and migration and binding affinity to MT1 melatonin receptor (MT1Rs) and estrogen 
 v
receptor 1 (ESR1) were assessed. The melatonin-tamoxifen drug conjugate linked with four (C4) 
or five (C5) carbons demonstrated the most favorable pharmacological characteristics with respect 
to potency and efficacy to inhibit BC cell viability and migration. C4 and C5 also exhibited unique 
binding profiles (affinity for ESR1 and MT1R) compared to the other conjugates. C4 and C5 were 
further assessed for their actions against tamoxifen-resistant (TamR) MCF-7 cells and patient-
derived xenograft triple-negative BC cells (TU-BcX-4IC) as well as for potential mechanisms of 
action using selective MEK1/2, MEK5, and PI3K inhibitors. C4 and C5 inhibited TamR MCF-7 
cells with equal potency and efficacy and both C4 and C5 inhibited TU-BcX-4IC cell viability. 
Even though both compounds demonstrated similar inhibitory actions against BC cell viability and 
migration, how this occurred, at a mechanistic level, was quite different between C4 and C5 in the 
cell lines. The underlying mechanisms of C4 and C5 in BC cell lines were context-specific and 
involved ERK1/2, ERK5, PI3 kinase, and NF-κB. They also exhibited unique pharmacokinetic 
profiles, where C4 had higher relative oral bioavailability than C5. These melatonin-tamoxifen 
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Chapter 1: Review on Breast Cancer 
Cancer is a major health problem worldwide and the second leading cause of death in the 
United States (Heron, 2019). Breast cancer (BC) is the most common cancer for women regardless 
of ethnicity and the leading cause of cancer-related death in women (G. N. Sharma et al., 2010). 
The treatment options for BC depends on the type and stage of cancer (G. N. Sharma et al., 2010). 
However, treatment failure can occur at any stage because of various factors such as patient 
compliance or resistance (Tang et al., 2016). Although significant improvements occurred in BC 
treatment and outcomes, further research is still required for safe, effective therapeutic options. 
 
1.1. Prevalence and Risk Factors 
According to the World Health Organization, BC affects about 2.1 million women 
worldwide each year, where BC deaths were estimated at 627,000 in 2018, which is 15% of all 
cancer-related deaths (2019). It is estimated that 41,760 BC patients will die because of BC in 
2019, which is 6.9% of all cancer-related deaths (N et al., 2018). About 1 in 8 women have a risk 
of developing BC during their lifetime (Bunker et al., 1998). Several risk factors such as age, 
genetic mutations, reproduction, family history, and hormone replacement therapy can predispose 
BC risk (Singletary, 2003). Lifestyle factors (i.e. physical activity, smoking, alcohol, hormone 
therapy, certain medications) can also play a crucial role in BC development (Singletary, 2003). 
1.2. Classifications 
BC can be classified based on different factors such as size, metastasis, receptor expression, 
and grade. Based on the receptor expression profiling, five molecular subtypes exist. 
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1.2.1. Luminal A and B 
Luminal A BC expresses estrogen receptors (ERs), progesterone receptors (PRs), and have 
low Ki67 expression. They are usually responsive to hormonal therapy or chemotherapy. MCF-7, 
T47D, and SUM185 are cell lines that have these characteristics in that they are low in Ki67 and 
responsive to endocrine therapy (Holliday & Speirs, 2011). Luminal B BC express ER, PR, HER2, 
and high Ki67. They are usually responsive to hormone therapy, chemotherapy, and HER2 
therapy. BT-474 and ZR-75 are cell lines that have these characteristics and are referred to as 
triple-positive BC cells. Fallahpour et al. reported that luminal A type accounts for 59% of total 
cases and showed a lower death rate of 2.2%; whereas luminal B accounts for 13.5% of total cases 
and a death rate of 11.8% (Fallahpour et al., 2017). 
1.2.2. Basal 
Basal type BC cells are negative for ER, PR, or HER2 and are referred to as triple-negative 
breast cancer (TNBC). They are not responsive to hormone therapy, but responsive to 
chemotherapy. Examples of this type of cancer are the MDA-MB-468 and SUM190 cell lines. 
Basal subtypes represent approximately 15% of total BC cases and demonstrate high mortality and 
high rates of recurrence (Milioli et al., 2017). 
1.2.3. HER2-positive 
This BC overexpresses HER2 and is responsive to therapies targeting the HER2 receptor-
like trastuzumab as well as chemotherapy. The human BC lines, SKBR3 and MDA-MB-453, and 
mouse mammary carcinoma cells (MMCs) have these characteristics. HER2-positive BC accounts 




Claudin-low BC does not express ER, PR, or HER2. In addition, Ki67, E-cadherin, claudin-
3, claudin-4, and claudin-7 expression are low. This type of BC is responsive to chemotherapy. 
MDA-MB-231 and BT-549 are BC cells with these characteristics and they are referred to as 
TNBC and claudin-low cell lines. MDA-MB-231 cells also harbor a KRAS/BRAF mutation while 
BT-549 cells have a PTEN mutation, which will be an important consideration when identifying 
the molecular mechanisms underlying some of the melatonin-tamoxifen drug conjugates’ actions 
in these cell lines. Approximately 7-14% of invasive BC are claudin-low (Dias et al., 2017). 
Claudin-low is considered a complex additional phenotype that can be divided into various 
intrinsic subtypes (Fougner et al., 2020). Claudin-low subtypes can be found in 14.6% of all basal-
like tumors (Fougner et al., 2020). Claudin-low tumors show a lower proliferation rate compared 
to basal-like tumors (Fougner et al., 2020). 
 
1.3. Therapies and limitations 
There are many options regarding BC management, which includes surgery, radiotherapy, 
chemotherapy, endocrine therapy, immunotherapy, targeted therapy, and conjugate therapy 
(Hasan et al., 2018; X. Wang et al., 2019). The treatment choice varies depending on different 
factors such as type, stage, invasiveness, and cost. Breast-conserving surgery and radiation therapy 
are usually preferred for stage I and II BC, whereas chemotherapy alone or chemotherapy followed 
by mastectomy is used for stage III BC patients (Maughan et al., 2010). A retrospective analysis 
reported that there was a significant increase in treatment costs for advanced stage (stage III) BC 
patients compared to the early-stage (stage I or II) patients (Blumen et al., 2016). For example, the 
average cost per patient allowed by the insurance company increased by 58% between stage I or 
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II ($82,121) BC and stage III BC ($129,387), which was mostly due to the cost of chemotherapy 
(Blumen et al., 2016). 
1.3.1. Surgery 
Tumors contained locally within the breast can be removed by surgery (Urruticoechea et 
al., 2010). Surgical options have been changed over the past two decades (Becker, 2015). For 
example, breast-conserving surgeries are being promoted along with radiation instead of radical 
mastectomy (Becker, 2015). Breast-conserving surgery (mastectomy) is often performed based on 
the reconstruction requirement where only the malignant tumor is removed to conserve normal 
tissues (Becker, 2015). While other therapies can only kill a fraction of cancer cells, complete 
removal of BC cells is possible by mastectomy (Urruticoechea et al., 2010). Tumor relapse post-
surgery depends on the type of operation, post-operative therapy, receptor status, and lymph node 
status. For example, 5-year local recurrence after lumpectomy was found to be 2.1% (Arvold et 
al., 2011), while the 5-year local recurrence after mastectomy was found to be 6% when axillary 
nodes were devoid of cancer (RW, 2014). 
1.3.2. Radiotherapy 
Since the 1940s, radiotherapy has been used to reduce relapse after surgery (Ragaz et al., 
1997). While radiation therapy can cure 40% of cancer, it is limited to certain types of cancer 
(Urruticoechea et al., 2010). Data from 36 randomized trials conducted in 17,273 women 
demonstrated that local recurrence was three times lower for patients receiving radiotherapy after 
surgery compared to patients receiving surgery alone ("Effects of Radiotherapy and Surgery in 
Early Breast Cancer — An Overview of the Randomized Trials," 1995). After 15 years of follow-
up, a randomized trial conducted in 318 premenopausal women with node-positive BC concluded 
that combined radiotherapy and chemotherapy reduced the recurrence rate by 33% and mortality 
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rate by 29% compared to chemotherapy alone (Ragaz et al., 1997). Radiotherapy can be used as 
an effective adjuvant with other therapies such as tamoxifen, doxorubicin, methotrexate, 
fluorouracil, and cyclophosphamide (Gröhn et al., 1984; Overgaard et al., 1999; Recht et al., 1996). 
For example, radiotherapy plus tamoxifen exhibited a 36% disease-free survival compared to the 
tamoxifen alone (24% disease-free survival) (Overgaard et al., 1999). Radiotherapy although 
effective against BC produces adverse effects in the body like inducing secondary cancers or heart 
disease (Taylor et al., 2017). A systemic review and meta-analysis of 762,468 BC patients 
exhibited an increased risk of secondary cancer such as lung, esophagus, and sarcoma (Grantzau 
& Overgaard, 2015). Regarding heart disease, a population-based, case-control study conducted 
in 2168 women who received radiotherapy demonstrated that patients showed an increased rate of 
ischemic heart disease due to ionizing radiation exposure to the heart (Darby et al., 2013). 
1.3.3. Chemotherapy 
Chemotherapy was first introduced in the 1950s for nonsolid tumors, which showed a 
higher rate of success for solid tumors (Becker, 2015). Over the years, several chemotherapies 
such as cyclophosphamide, methotrexate, 5-fluorouracil, paclitaxel, docetaxel, capecitabine, 
vincristine, gemcitabine, and eribulin have been developed—each targeting different signaling 
pathways (Becker, 2015). Chemotherapy usually produces adverse effects in those tissues that 
have a faster rate of growth like skin, nails, and bone marrow. The failure rate for chemotherapy 
varies between 5% to 50%, which is dependent upon the type of drug used, tumor size, metastasis, 
lymph node status, hormone receptor status, and HER2 receptor status/grading (Becker, 2015). 
Chemotherapy is usually effective against TNBC, drug-resistant cancer, or non-responsive cancer 
because of its non-receptor-mediated actions and downstream targeting (Wahba & El-Hadaad, 
2015). Treatment of TNBC remains complicated compared to the hormone-positive and HER2-
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positive BC because of its aggressiveness and metastatic potential but also difficult to treat due to 
a lack of targeted therapies (Anders & Carey, 2008). Since TNBC does not respond to endocrine 
therapy or HER2-targeting agents (Anders & Carey, 2008), chemotherapy is the only option for 
TNBC or basal-like BC (Cancer Genome Atlas, 2012). 
1.3.4. Endocrine therapy 
Anti-estrogen therapies comprise a broad class of drugs that include aromatase inhibitors, 
selective estrogen receptor modulators (SERMs), and selective estrogen receptor downregulators 
(SERDs). This form of therapy is commonly used to treat estrogen-dependent and estrogen 
receptor (ER)-positive BC (Ali et al., 2016). 
Aromatase inhibitors, which act by reducing estrogen levels, can bind covalently 
(formestane and exemestane) with aromatase or non-covalently bind with the heme moiety 
(fadrozole, vorozole, rogletimide, letrozole, and anastrozole) (Chumsri et al., 2011). Aromatase 
inhibitors are well-tolerated with some common side effects such as hot flashes, vaginal dryness, 
and headache (Chumsri et al., 2011). Unlike tamoxifen, aromatase inhibitors do not increase the 
risk of endometrial cancer and thromboembolism because of their lack of estrogenic effects 
(Chumsri et al., 2011). Clinically aromatase inhibitors exhibit similar or superior efficacy 
compared to tamoxifen. For example, in one study comparing anastrozole to tamoxifen, a delay in 
disease progression from 23 weeks to 42 weeks was observed with aromatase inhibitors vs 
tamoxifen. However, in the TARGET trial comparing anastrozole to tamoxifen, no distinction in 
disease progression (8.2 months vs. 8.3 months) was observed (Chumsri et al., 2011). 
SERMs such as tamoxifen, raloxifene, and toremifene are a class of compounds that 
agonize or antagonize ERs in a tissue-dependent manner. Tamoxifen, which will be the focus of 
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this dissertation, antagonizes ERs to inhibit BC but acts as an agonist in the endometrium and bone 
(Johnston, 2001). Raloxifene came to the market in 1997 first as an anti-osteoporotic drug and then 
it was approved for use as a BC drug for ER+ BC in 2007 (Waters et al., 2012). Similar to 
tamoxifen, raloxifene antagonizes ERs in breast cells, whereas it differs from tamoxifen in that 
does not activate uterine ERs and stimulate the growth of uterine epithelium (Rey et al., 2009). 
Both tamoxifen and raloxifene, however, exhibit estrogenic actions in bone and serum cholesterol 
in ovariectomized rats (Sato et al., 1994). 
SERDs such as fulvestrant work differently than SERMs because they prevent ER 
dimerization from occurring making the ER monomers susceptible to proteolysis and degradation; 
this results in a loss of ER expression or down-regulation (Nathan & Schmid, 2017) (C. K. Osborne 
et al., 2004). Selective estrogen receptor downregulators can also inhibit AF1- and AF2-related 
transcriptional activity (Movérare-Skrtic et al., 2014). 
1.3.4.1. Tamoxifen and its clinical actions 
The first-generation SERM, tamoxifen, was developed in 1966 and is widely used for ER+ 
BC. It is approved by the FDA for both the prevention and treatment of ER+ BC in pre- and post-
menopausal women (Jaiyesimi et al., 1995; Minsun, 2012; Ring & Dowsett, 2004; Wapnir et al., 
2011). Several studies demonstrate significant tamoxifen efficacy against invasive and non-
invasive BC (Wapnir et al., 2011). Even though 20-30% of patients on tamoxifen therapy become 
resistant to it over time, it is the first drug of choice for ER+ BC because of its ability to reduce 
the mortality rate and relapse by 31% and 50%, respectively (Ali et al., 2016). Despite having the 
clinical benefit for treating BC, long-term use of tamoxifen can result in relapse (Ring & Dowsett, 
2004) and increase the risk of uterine cancer (Assikis & Jordan, 1997; Bernstein et al., 1999; Jones 
et al., 2012; van Leeuwen et al., 1994). Regarding the mechanisms underlying tamoxifen’s actions 
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on the uterus, it is through its estrogenic actions at ERs expressed in the endometrium possibly 
through recruitment of co-activators such as steroid receptor co-activator-1 (SRC-1), amplified in 
breast cancer-1 (AIB1), and CREB-binding protein (CBP) (Hu et al., 2015). Tamoxifen’s 
mechanisms of resistance will be discussed further in Section 1.6.4. 
1.3.4.2. Tamoxifen and its molecular actions 
Tamoxifen is a prodrug, which gets metabolized into 4-hydroxytamoxifen and endoxifen 
by liver cytochrome P450 enzymes (CYP26 and CYP3A4 isoforms) (Ali et al., 2016). Both 4-
hydroxytamoxifen and endoxifen have up to 100 times higher affinity for the ER compared to 
tamoxifen (Felker et al., 2016). A schematic of tamoxifen’s molecular action in BC has been 
described in Figure 1. Tamoxifen, following binding to ERs, recruit co-repressor proteins 
including NCoR, SMRT, and histone deacetylases (HDACs) reducing estrogen/ER-mediated gene 
expression. Tamoxifen, by antagonizing mitochondrial ER-β, can increase reactive oxygen species 
possibly through downregulation of manganese superoxide dismutase (Razandi et al., 2013).  
Besides having ER-dependent actions, tamoxifen can also inhibit BC in an ER-independent 
manner. For example, tamoxifen can induce apoptosis in cells independent of ERs (Bogush et al., 
2012) and promote apoptosis in C6 glioma cells by inhibiting PI3K/AKT and JNK while sustaining 
ERK1/2 activation (Feng et al., 2010). Tamoxifen can also induce mitochondrial stress by 
increasing intramitochondrial calcium levels through a NO-dependent pathway to enhance 
apoptosis; tamoxifen-mediated stimulation of NO synthase causes reduced cytochrome C release 
and suppression of mitochondrial respiration (Bogush et al., 2012). The finding that tamoxifen can 
stimulate ATPase suggests that tamoxifen may promote proton permeability due to a loss of 
mitochondrial inner membrane structural integrity (Cardoso et al., 2001). Tamoxifen can also 
modulate matrix metalloproteinases, which may or may not be favorable to breast cancer 
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protection. For example, tamoxifen can up-regulate matrix metalloproteinase 1, an enzyme 
involved in BC angiogenesis and invasiveness, and tissue inhibitor of metalloproteinases-1, a 
protein that promotes BC cell proliferation and anti-apoptosis. However, tamoxifen can also 
downregulate metalloproteinase 9, a protein involved in tumor vascularization and also known to 
be involved in metastases in MCF-7 cells, which would prevent BC (Cheng et al., 2016; Eck et al., 
2009; Mehner et al., 2014; Nilsson et al., 2007). 
 
Figure 1: Molecular action of tamoxifen in BC. Tamoxifen demonstrated a multitude of 
actions in BC cells. It can inhibit nuclear ER while activating membrane-bound ER. It can block 
JNK and PI3K pathway while sustaining ERK1/2 activation. Tamoxifen can also modulate BC 
angiogenesis, invasiveness, vascularization, metastasis, apoptosis, and proliferation by regulating 
MMPs and TIMP1. Furthermore, tamoxifen can produce mitochondrial stress and apoptosis 
through the regulation of ER- β, calcium level, NO synthase, and ATPase. MMP = Matrix 
Metalloproteinases, TIMP1 = Tissue Inhibitor of Metalloproteinases-1, MnSOD = manganese 
superoxide dismutase. 
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1.3.5. Targeted therapy 
Targeted therapy usually regulates a target receptor or specific signaling protein in cancer 
cells by the use of monoclonal antibodies or small molecule inhibitors. For example, monoclonal 
antibodies that inhibit HER2 (e.g., trastuzumab and pertuzumab b) have been approved by the 
FDA to treat HER2-positive BC (Appert-Collin et al., 2015) while signaling proteins, CDK4/6, 
PARP, and PI3K, involved in cell proliferation, cell survival, cell growth, and DNA repair, are 
targeted using small molecule inhibitors (Breast Cancer Facts & Figures 2019-2020, 2019; Nur 
Husna et al., 2018). In this dissertation, immunotherapy is discussed under the section on targeted 
therapy. However, some immunotherapies such as interleukins and interferons, might not be 
considered “targeted” when the therapy affects non-cancerous cells (Monjazeb et al., 2012). 
1.3.5.1. Immunotherapy 
The immune system actively works in recognizing and destroying cancer cells where T-
cells are activated by the cancer neoantigen signaling through Antigen Presenting Cells (APCs) 
(García-Aranda & Redondo, 2019). Activated CD8+ T-cells are considered the main effectors in 
killing aberrant cells. CD8+ T-cells can enhance CD4 T-helper cell activity and increase B cell 
antibody production (Pross & Lefkowitz, 2007). However, different types of immune cells can act 
differently on the tumor. Innate immune cells play a role in tumor proliferation, tumor elimination, 
promote metastasis, and inhibition of tumor cell transformation (Gonzalez et al., 2018). For 
example, T cell infiltration exhibits a good prognosis on solid tumors, whereas macrophage 
infiltration demonstrates poor prognosis (Gonzalez et al., 2018). 
After the engagement of major histocompatibility complexes (MHCs) with T cell receptors 
(TCRs), CD28 binds to CD80/86 for further T cell activation (Abril-Rodriguez & Ribas, 2017). 
Binding of CD28 to CD80/86 can be inhibited by cytotoxic T lymphocyte-associated antigen 4 
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(CTLA-4) in the early stage of T cell activation in the lymph nodes (Abril-Rodriguez & Ribas, 
2017). Cancer cells can further prevent the action of T cells by blocking programmed cell death 1 
(PD-1) receptor by expressing PD-L1 or PD-L2 ligands (Abril-Rodriguez & Ribas, 2017). 
Monoclonal antibodies targeting CTLA-4, PD-1, PD-L1, and immune checkpoint proteins, 
have been approved by the FDA to treat different cancers such as melanoma, lung cancer, 
Hodgkin’s lymphoma, renal carcinoma, Merkel cell carcinoma, urothelial carcinoma, bladder 
cancer, head and neck cancer (Abril-Rodriguez & Ribas, 2017); clinical trials on immune 
checkpoint inhibitors are ongoing for BC patients (Cesar & Rita, 2018). An anti-PD-1 antibody, 
pembrolizumab, demonstrates an 18.5% to 23% response rate in TNBC patients (Adams et al., 
2017; Nanda et al., 2016) and a 12% response rate in ER+/HER2- advanced breast cancer patients 
(Basu et al., 2019). Although well-tolerated, these immune checkpoint inhibitors are unable to 
prevent relapse and metastasis (Basu et al., 2019). The CTLA 4 blocker, tremelimumab, plus 
exemestane exhibit stable disease conditions in 42% of metastatic ER+ patients (Vonderheide et 
al., 2017). In a pilot study, a preoperative single dose of ipilimumab (anti-CTLA4) and 
cryoablation exhibit intratumoral and systemic immunologic effects (McArthur et al., 2016). 
1.3.6. Antibody drug conjugates 
Antibody drug conjugates (ADCs) are immunoconjugates where an antibody is usually 
attached to a cytotoxic drug. Although ADCs are one of the fastest growing classes of cancer 
therapeutics and several ADCs are under investigation, only Kadcyla® (Trastuzumab emtansine 
conjugate) has been approved by the FDA for HER2-positive metastatic BC patients and other 
HER2 targeting drug conjugates are also on clinical trials (Hasan et al., 2018; Lambert & Chari, 
2014). Details of ADCs are discussed further in section 1.7.1.1. 
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1.4. Estrogen receptors (ERs) and ER-mediated signaling pathways 
Numerous receptors (ER, HER2, and ErbB) and/or signaling pathways (i.e., MAPK, Wnt, 
Hedgehog, PI3K, mTOR, JAK/STAT, TGF, and Notch) play critical roles in tumor progression, 
cell growth, apoptosis, and drug resistance (McCubrey et al., 2016). Because of their important 
role in BC pathogenesis, they are targets of myriad cancer drugs including tamoxifen. 
1.4.1. ER physiology, pharmacology, and signaling 
Estrogens play critical roles in both female and male reproduction, including mammary 
development in females (Molina et al., 2017) and sperm maturation in males (Molina et al., 2017). 
Estrogens also are important in cardiovascular, skeletal, and nervous system functions (Molina et 
al., 2017). Endogenous estrogens such as estrone (E1), estradiol (E2), and estriol (E3) bind to and 
activate nuclear ERs through passive diffusion due to their hydrophobic nature (Molina et al., 
2017). Estrogens can also bind to and activate membrane-bound ERs, GPR 30, and activate 
downstream proteins (Figure 2). 
ERs are classified as non-genomic (membrane-bound G-protein coupled receptor) or 
genomic (ERα and ERβ) (Saha Roy & Vadlamudi, 2012a). The ERα-expressing gene, which 
encodes for a 595 amino acid protein, is located on chromosome 6 whereas the ERβ-expressing 
gene, which encodes for a 530 amino acid protein, is located on chromosome 14 (Jameera Begam 
et al., 2017) making them unique gene products and not splice variants. ERα, which has a 
molecular weight of 66 kDa is larger than ERβ, which has a molecular weight of 54 kDa (Jameera 
Begam et al., 2017). The genomic ERs modulate intracellular responses via estrogen response 
elements (EREs), which is a 28-nucleotide sequence consisting of 5′-GATCTCGAGTCAGGT-
CACAGTGACCTGA-3′ that lay upstream of various genes and promoter sequences. 
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Estrogen modulates ER-dependent gene transcription by the following sequence described 
in Figure 2. In brief, estrogen, following binding to ERs, promotes ER dimerization and 
translocation to EREs located on genes. Gene transcription occurs following the activation of 
histone acetyltransferase (HAT) proteins, which acetylates lysine residues on histone binding 
proteins releasing their binding to DNA. ER-ERE mediated gene transcription can be enhanced by 
co-activators (e.g., SRC1, NCoA2, NCoA3, and CREB-binding protein) and can be suppressed by 
co-repressors (e.g., NCoR1 and NCoR2) (Ring & Dowsett, 2004). Moreover, other receptors (e.g., 
IGFR, EGFR, and HER2), cytokines, and stress can phosphorylate ERs through the activation of 
AKT, ERK1/2, and p38 pathways (Ring & Dowsett, 2004). 
ERα can activate Src kinase, mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K), and protein kinase C pathways (Saha Roy & Vadlamudi, 
2012b). A detailed mechanism of the MAPK pathway is described in Figure 3. 
The PI3K-AKT-mTOR pathway plays an important role in cell survival; and dysregulation 
of this pathway may induce endocrine resistance (Mohamed et al., 2013). Mutation in the PI3KCA 
gene is the most frequent genetic abnormality in ER+ BC, whereas a somatic mutation in TP53, 
PIK3CA, and GATA3 occurs in more than 10% of all BC (Xiang et al., 2012). Cytosolic activation 
of ERK and AKT can induce cell migration (Saha Roy & Vadlamudi, 2012b). ERs can also interact 
with kinases in the cytoplasm and membrane via a non-genomic pathway (Ring & Dowsett, 2004). 
 The estrogen-mediated actions on ERK1/2 occur in human HER2 (SKBR-3) BC cells that 
are ERα and ERβ negative demonstrating that these estrogen-mediated actions on ERK1/2 
probably are occurring through the non-nuclear estrogen receptor, GPR30 (Molina et al., 2017). 
GPR30 (also known as GPER-1) is a seven-transmembrane G-protein coupled receptor that 
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contains 375 amino acids with a molecular weight of 41 kDa (Hsu et al., 2019; Molina et al., 2017). 
Estrogen-induced signaling through GPR30 is considered a non-classical pathway. GPR30 can 
increase cAMP formation and intracellular IP3, which can transactivate EGFR or activate 
PI3K/AKT or ERK1/2 pathways (Molina et al., 2017). For example, inhibition of GPR30 
downregulates PI3K and p-AKT expression and blocks SKBR-3 BC cell proliferation (Shi et al., 
2020). GPR 30 activates transcription factors such as Fos/Jun activating protein-1 by binding with 
co-activators (Ring & Dowsett, 2004). See Figure 2 for the detailed schematic.                                                       
 
Figure 2: Mechanism of ER of genes transcription through ER-ERE complex. This schematic 
is taken from (Egeland et al., 2015), licensed under CC BY 4.0 
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(https://creativecommons.org/licenses/by/4.0/). ER is activated by estrogen (E) that dimerize and 
translocate to the nucleus. The dimer binds with ERE or serum response element (SRE). ER-ERE 
complex recruits co-activators such as HATs to induce gene transcription, whereas ER-SRE 
complex also recruits transcription factors such as AP-1 and AP-2. In the non-classical pathway, 
E can bind with GPR30, RTKs, or other receptors. Depending on the type of receptor, E can 
activate secondary messenger (SM) or PI3K-AKT pathway. ER can stimulate ERK or transactivate 
RTKs in a ligand-independent manner. RTKs further phosphorylate genomic ER. PI3K/AKT 
pathway and ERK activation can further activate transcription factors bound to the response 
element. 
1.4.2. ERs and their role in BC 
Estrogen, directly or through its cognate receptors, can cause BC. Even though estrogen, 
specifically through its quinone metabolites, can induce mammary cancer through DNA damage 
(Yue et al., 2013), most of the estrogen’s cancer-promoting actions occur through ERs. Most 
(70%) of total BC cases are ER-positive (Mohibi et al., 2011). The mechanisms by which ERs 
play a role in BC are diverse and include estrogen/ER-mediated actions as well as non-estrogen-
mediated actions. For example, in the absence of estrogen, ERα can attach to an Hsp90 multi-
chaperone complex in the cytosol (Renoir et al., 2013). After ligand-activation, Hsp90 is released 
from the ER and active ERs dimerize and translocate to the nucleus (Renoir, Marsaud, & Lazennec, 
2013). After translocation, the ER dimer binds to the ERE and recruits co-activators such as SRC1, 
AIB1, and CBP, which have histone acetyltransferase activity, to induce ER/ERE-regulated genes 
(Saha Roy & Vadlamudi, 2012a). Moreover, studies demonstrate that chronic estradiol exposure 
results in ER/ERE-mediated downregulation of transcriptional repressors that regulate anti-
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proliferative and pro-apoptotic genes (Frasor et al., 2003) and upregulate tumor promoters like 
AF-1 and AF-2 (Ring & Dowsett, 2004). 
ERα and ERβ can exhibit different actions in normal mammary epithelial cells. For 
example, the ERα-ERE complex can induce several gene transcripts such as the cyclins and c-
myc, which are related to cell proliferation, migration, differentiation, invasion, metastasis (Renoir 
et al., 2013). ERβ inhibits cell proliferation by arresting cells in G2 of the cell cycle, by inhibiting 
c-myc, cyclin D1, and cyclin A (Paruthiyil et al., 2004). Coactivators can be differentially 
expressed and their functions can be altered in tumors (Saha Roy & Vadlamudi, 2012b). Histone 
acetyltransferases (HATs), DNA-methyl transferases (DNMTs), and histone deacetylases 
(HDACs) can regulate gene transcription by altering chromatin structure (Mohamed et al., 2013). 
Histone modulators can act as coactivators/corepressors for several nuclear receptors such as ER. 
Studies demonstrate that methylation within the ERα gene promoter decreases ERα gene 
transcription (Yoshida et al., 2000). Cell proliferation markers such as Ki67 and cyclin A are 
related to ERβ expression in BC (Jameera Begam et al., 2017). An interaction between ERs and 
the cyclin-dependent kinases, CDK4/6, can lead to endocrine resistance by persistent cyclin D1 
expression and retinoblastoma (Rb) phosphorylation (Mohamed et al., 2013). CDK4/6 kinases 
regulate G1-to-S1 phase transition by interacting with cyclin D while phosphorylated Rb releases 
E2F transcription factors and genes that are responsible for cell division (Mohamed et al., 2013). 
GPR30, the membrane-bound ER, plays an important role in BC pathogenesis as it is 
expressed in about 50-60% of all BC. The mechanisms underlying GPR30 action in BC is through 
EGFR, cAMP, and ERK pathways to modulate cell proliferation and migration. Evidence for this 
comes from studies in cells whereby knock-down of GPR30 in TNBC cells results in an inhibition 
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of cell proliferation and estrogen-mediated EGFR activation (Girgert et al., 2012). In ER-negative 
BC cells, activation of GPR30 results in cAMP-mediated inhibition of EGFR/ERK (Filardo et al., 
2002). Finally, in inflammatory BC cells, GPR30 activation by GPR30-selective agonists increases 
migration and invasiveness through cyclin E, CXC receptor-1, and the notch pathway (Lappano et 
al., 2014). 
GPR30 may be involved in tamoxifen resistance. For example, tamoxifen-resistant BC 
cells exhibit GPR30 upregulation due to estrogenic stimulation. A GPR30 agonist, G-15, improves 
tamoxifen sensitivity in tamoxifen-resistant MCF-7 cells possibly due to increases in GPR30 
expression (Lappano et al., 2014). In a cohort study conducted in 103 patients, it was found that 
GPR30 negatively correlates with relapse-free survival in tamoxifen-treated patients (Ignatov et 
al., 2011). However, studies demonstrate that GRP30 acts as a pro-apoptotic and tumor suppressor 
protein (Hsu et al., 2019). GPR30 mRNA expression is downregulated in both ER-positive and 
ER-negative BC tissues compared to the normal tissues, suggesting a correlation between low 
GPR30 and metastasis to the lymph node (Poola et al., 2008). These mixed effects of GPR30 action 
on BC may be due, in part, to the type of BC because in some BC cells (e.g., SKBR-3-HER2), 
GPR30 stimulates cell growth while in others (e.g., MCF-7-ER+), GPR30 inhibits cell growth 





Figure 3: Signaling pathways driving ERK activation, effectors, and cellular processes 
regulated by this kinase. This schematic is taken from (Olea-Flores et al., 2019), licensed under 
CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). MEK1/2 can be activated by B-RAF 
RTKs, GPCRs, extracellular matrix, and Ca2+ ions. ERK1/2 can be phosphorylated by p-MEK1/2 
and translocate to the nucleus, where it activates transcription factors such as Elk1, Ets1/2, and c-
Myc. ERK1/2 and/or MEK5 can phosphorylate ERK5. Translocated ERK5 activates transcription 
factors such as MEF2, Ets1/2, and c-Myc. ERKs-mediated gene transcriptions play a role in cell 
division, survival, differentiation, motility, and epithelial-mesenchymal transition. 
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1.4.3. Heterologous modulation of ERs and ER-mediated signaling 
ErbB receptor. Erythroblastosis oncogene-B (ErbB) or human epidermal growth factor receptor 
(HER) is a receptor family classified as receptor tyrosine kinase (Appert-Collin et al., 2015), The 
ErbB family has four receptors: ErbB1 (EGFR/HER1), ErbB2 (HER2/Neu), ErbB3 (HER3), and 
ErbB4 (HER4) (Appert-Collin et al., 2015). ErbB receptors can regulate cell proliferation, 
migration, and differentiation (Appert-Collin et al., 2015). ErbB2 receptor has no known ligand 
and so it dimerizes with other ErbB proteins for transactivation. It is overexpressed in almost 20% 
of BC (Moreno-Layseca et al., 2017). ErbB2 can modulate ductal elongation and branching in 
mammary epithelium and can induce cell proliferation (Moreno-Layseca et al., 2017). 
A relationship exists between ERs (including GPR30) and ErbB where each can modulate 
the other; this may occur through common intracellular signaling proteins like AKT and MAPK 
or through direct modulation of receptor activity and/or levels. For example, in HER2 
overexpressed cells, AKT and MAPK demonstrate reduced ER expression (Giuliano et al., 2013). 
However, in ER+ BC, AKT and MAPK can phosphorylate ER and its coactivators to increase ER 
activity; this has been proposed to be a potential mechanism underlying endocrine therapy 
resistance in ER+ BC (Giuliano et al., 2013). Co-modulation between ERs and HER2 has also 
been demonstrated in studies that result in altered receptor function; this may be due, in part, to 
phosphorylation processes. For example, heregulin, a HER2 agonist, can rapidly phosphorylate 
ERs (Bender & Nahta, 2008) while GPR30 can activate HER2 (Giuliano et al., 2013). ER+ BC 
cells that were originally sensitive to both estrogen and tamoxifen become resistant to each when 
these cells are transfected (or overexpressed) with HER2 (Bender & Nahta, 2008). In tamoxifen-
resistant BC, increases in ERK1/2 and HER2 phosphorylation is observed (Bender & Nahta, 
2008). These findings suggest that both HER2/ErbB2 and ER bidirectionally modulate one another 
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to impact their activity possibly through phosphorylation processes directed at the receptors and/or 
downstream signaling proteins. 
Melatonin receptor. Melatonin, which is discussed in detail below, can inhibit ER signaling. This 
primarily occurs through inhibition of ER binding to EREs to decrease the transcriptional activity 
of ERα and/or coactivator phosphorylation. These actions of melatonin appear to be specific for 
ERa as no effect was observed on ERb (Hill et al., 2015). 
 1.5. Melatonin receptors, physiology, pharmacology, and signaling 
1.5.1. Melatonin’s role in physiological processes 
Melatonin is an ancient molecule estimated to be billions of years old (Manchester et al., 
2015). It is hypothesized that melatonin evolved from purple-containing bacteria. Because 
primitive eukaryotes engulfed bacteria during the early phases of evolution, all species can 
synthesize melatonin in the mitochondria and/or chloroplast; it was during these early stages of 
evolution whereby melatonin primarily functioned as an antioxidant (D. Zhao et al., 2019). 
In humans, melatonin synthesis occurs in the pineal gland, retina, gastrointestinal tract, 
skin, bone marrow, and lymphocytes (Hill et al., 2015). However, the pineal gland is the main 
organ that synthesizes melatonin in the absence of light perception (Maria & Witt-Enderby, 2014; 
P. A. Witt-Enderby et al., 2006). In the classical pathway, melatonin is synthesized from 
tryptophan precursor (D. X. Tan et al., 2016b). Aromatic amino acid decarboxylase (AADC) 
converts 5-hydroxytryptophan into 5-hydroxytryptamine (serotonin). Serotonin then gets 
acetylated to N-acetylserotonin by arylalkylamine N-acetyltransferase (AANAT), which then is 
methylated to melatonin by N-acetylserotonin O-methyltransferase (ASMT) (D. X. Tan et al., 
2016b). 
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The rhythm and secretion of melatonin are under the control of an endogenous (near 24 hr) 
oscillator generated spontaneously through nuclei that reside in the suprachiasmatic nucleus (SCN) 
of the hypothalamus. The eyes, specifically melanopsin in retinal ganglion cells, which are cells 
distinct from rods and cones, can also regulate the SCN endogenous clock through the 
retinohypothalamic tract. Melanopsin has an absorption spectrum distinct from that of rods and 
cones with a wavelength of approximately 480nm (blue light range). So, although melatonin 
synthesis and secretion are generated by the endogenous clock, the eyes entrain these rhythms to 
the light/dark cycle (Lockley et al., 2007). For the most part, the physiological concentration of 
melatonin in the body is regulated by the pineal gland’s response to light and the organ most 
responsible for its metabolism—the liver (Kelleher et al., 2014). 
Although melatonin modulates numerous physiological functions in the body through 
myriad signaling cascades, the focus of this dissertation will be on its anti-BC actions and 
associated signaling pathways. 
 
1.5.2. Melatonin’s role in BC 
Epidemiological evidence demonstrates that decreased melatonin levels due to aging, light 
exposure at night, and shift work is associated with BC risk (David E. Blask et al., 2005b; S. Davis 
et al., 2001; Grant et al., 2009; Schernhammer et al., 2001; P. A. Witt-Enderby et al., 2006). Also, 
a lower level of melatonin induced by a 1 hr light exposure at night increases tumor growth in 
rodents (David E. Blask et al., 2005b; S. Davis et al., 2001; Grant et al., 2009; Schernhammer et 
al., 2001). Hence, the data suggest that decreased levels of melatonin due to aging and light 
exposure at night are associated with increases in tumor growth. 
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1.5.2.1. Melatonin’s direct role in BC 
The observation that levels of melatonin are higher in neoplastic breast tissues compared 
to serum suggest that melatonin has a direct action on BC (P. A. Witt-Enderby et al., 2006). In 
support of this, physiological concentrations of melatonin (1nM to 100nM) significantly inhibit 
MCF-7 cell proliferation; the morphological characteristics of these cells also demonstrate reduced 
surface microvilli, nuclear swelling, cytoplasmic and ribosomal shedding, and increased 
autophagic vacuoles (Hill & Blask, 1988). Melatonin also reduces aromatase activity, the enzyme 
responsible for estrogen production, and increases p53 and p21WAF21 expression in MCF-7 cells 
(Cos et al., 2005; Mediavilla et al., 1999). In a variety of rodent models, melatonin supplementation 
or optimum nocturnal melatonin levels demonstrate BC protection (David E. Blask et al., 2005b; 
Robert T. Dauchy et al., 2014b; V. Davis et al., 2011a; Grant et al., 2009; Hill et al., 2015). 
1.5.2.2 Melatonin’s role as an adjuvant in BC 
Melatonin can regulate apoptosis, angiogenesis, metabolism, and cell migration, and it 
possesses antioxidant activity (Favero et al., 2018). However, because of its other unique 
properties—free radical scavenger and anti-oxidant—melatonin has also been shown to be an 
effective adjuvant to enhance the efficacy of cancer therapies as well as reduce the adverse effects 
and toxicities associated with them (V. L. Davis et al., 2011b; Grant et al., 2009; P. Lissoni et al., 
1996; Sabzichi et al., 2016; P. A. Witt-Enderby et al., 2006). For example, a combination of 
melatonin with anti-estrogen therapies (i.e., tamoxifen or anastrozole) improves the survival and 
quality of life in metastatic BC patients (P. Lissoni et al., 1995; Paolo Lissoni et al., 2009; P. 
Lissoni et al., 1996). Melatonin has also been shown to increase the efficacy of tamoxifen in 
tamoxifen-unresponsive metastatic BC patients (P. Lissoni et al., 1995) while other studies suggest 
that tamoxifen can comodulate melatonin receptor activity in breast and ovarian cancer cells 
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enhancing melatonin’s anti-cancer actions (Treeck et al., 2006). These findings suggest that 
tamoxifen and melatonin can cross-modulate ERs and MTRs, respectively, to enhance tamoxifen’s 
actions at ERs and melatonin’s action at MTRs. 
This benefit of melatonin on tamoxifen resistance also extends to tamoxifen-resistant 
models in rodents and cells. For example, melatonin increases the efficacy of tamoxifen in MCF-
7 cells (Sabzichi et al., 2016). Moreover, melatonin can reverse tamoxifen resistance due to light 
exposure at night and depletion of nocturnal melatonin levels (D. E. Blask et al., 2005a; R. T. 
Dauchy et al., 2014a; Grant et al., 2009). The mechanisms underlying this reversal in tamoxifen 
resistance may be through the downregulation of ERK1/2, AKT, SRC, NF-κB, STAT3, and 
CREB, which can mediate tamoxifen resistance in BC (R. T. Dauchy et al., 2014a). Melatonin can 
suppress estrogen-mediated ERα transcriptional activity through Gαi protein (Hill et al., 2009). 
1.5.3. Melatonin receptor-dependent and -independent actions, associated signaling cascades 
and their role in BC 
1.5.3.1. Melatonin’s receptor-independent and anti-cancer actions 
Melatonin can work as a paracoid, autocoid, antioxidant, and free radical scavenger in a 
receptor-independent manner (Reiter et al., 2007). Melatonin’s lipophilic properties enable it to 
cross the plasma membrane to reach cytosolic, mitochondrial, and nuclear proteins (Hill et al., 
2015). Melatonin can decrease adenylyl cyclase (AC) activity and cAMP production by binding 
with calmodulin directly, which can enhance cellular differentiation and suppress cell proliferation 
(Hill et al., 2015; P. A. Witt-Enderby et al., 2006). Furthermore, antioxidant enzymes such as 
superoxide dismutase, glutathione peroxidase, and glutathione reductase can be activated by 
melatonin, which can reduce free hydroxy radical formation (Reiter et al., 2007). Melatonin can 
also detoxify free radicals directly by donating one or more electrons and while detoxifying 
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melatonin produces metabolites that are equally or better free radical scavengers compared to the 
melatonin (Reiter et al., 2007). In vitro, melatonin synergizes with vitamins C and E to enhance 
their activity (Reiter et al., 2007). In terms of potency to inhibit lipid peroxidation, melatonin, 
vitamin C, vitamin E, and glutathione demonstrate IC50 values of 426, 4325, 4, and 2290 µM, 
respectively (Gitto et al., 2001). However, melatonin exhibits better efficacy in inhibiting free-
radical–based molecular destruction compared to vitamin C, vitamin E, and β-carotene (Korkmaz 
et al., 2009). 
1.5.3.2. Melatonin, melatonin receptors, and their anti-cancer actions 
Regarding its receptors, three subtypes of melatonin receptors exist initially named Mel1a, 
Mel1b, and Mel1c. However, based on IUPHAR nomenclature, these receptors were renamed 
from Mel1a and Mel1b to MT1R and MT2R, respectively, because of their expression in 
mammalian cells (Dufourny et al., 2008). Mel1c is found only in Xenopus species and chicken 
(Dufourny et al., 2008). GPR50, an orphan receptor found only in eutherial mammals, is 
considered an ortholog of Mel1c which heterodimerizes with MT1R and MT2R, has been 
demonstrated to modulate MT1R affinity for melatonin (Dufourny et al., 2008). All three subtypes, 
except for GPR50 where no binding was observed, have a high affinity (MT1R, Kd=0.1 nM; 
MT2R, Kd=0.1 nM; Mel1c, Ki=1 nM) for endogenous melatonin (Clement et al., 2017; Liu et al., 
2019). A detailed mechanism of melatonin’s action is described in Figure 4. The human melatonin 
receptors, MT1 and MT2, are G-protein coupled receptors located at the plasma membrane and for 
the MT1 receptor, also in the mitochondria (Cecon et al., 2018; Suofu et al., 2017). The 
mitochondrial MT1 receptor can inhibit stress-mediated cytochrome c release and caspase 
activation to provide neuroprotection in the brain (Suofu et al., 2017). 
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Melatonin, through activation of melatonin receptors, MT1 and MT2, can exhibit anti-
cancer activity through several mechanisms. Melatonin receptors through Gαi/o proteins inhibit 
adenylyl cyclase and cAMP, which reduces linoleic acid uptake (Molina et al., 2017). Melatonin 
decreases telomerase activity in MCF-7 xenografts of nude mice, which is essential for telomere 
elongation (Leon-Blanco et al., 2003). Melatonin can down-regulate angiogenesis-associated 
genes such as EPAS1, NDRG1, and EFNA1 to prevent tumor metastasis through MT1R (Hill et 
al., 2015). Melatonin through MT1 melatonin receptors suppresses transactivation of other nuclear 
receptors such ER, glucocorticoid receptor, RORα in BC cells and can potentiate the 
transactivation of RARα, RXRα, vitamin D receptor, and PPARγ (Hill et al., 2015). Melatonin 
activity on ER has already been described in section 1.4.3. Few studies suggested that melatonin 
can also bind to the retinoid orphan nuclear receptors (Cos et al., 2005).  
Recently, melatonin receptors have been identified in the mitochondria. The mitochondria 
are important cellular organelles because of their importance in energy (ATP) production. The 
mitochondria can produce free radicals such as superoxide anion (O2ꞏ-) during ATP production 
via the electron transport system, whereas, excessive production of free radicals may cause 
oxidative stress and cell death (D.-X. Tan et al., 2016a). Excessive free radicals can induce 
hydrogen peroxide production and/or cellular death (D.-X. Tan et al., 2016a).  
Besides expressing melatonin receptors, the mitochondria also contain high concentrations 
of melatonin against the concentration gradient (D.-X. Tan et al., 2016a). This finding and that 
AANAT, one of the enzymes involved in melatonin synthesis, and melatonin metabolites are found 
in the mitochondria indicate that the mitochondria may be able to synthesize and metabolize 
melatonin (D.-X. Tan et al., 2016a). Melatonin is a potent free radical scavenger and 
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mitochondrial-targeted antioxidant (D.-X. Tan et al., 2016a) and so its presence in the 
mitochondria is not unexpected. Suofu et al. showed that the mitochondria can synthesize 
melatonin and that mitochondrial MT1R can inhibit cytochrome c release and caspase activation 
through GPCR signaling (Suofu et al., 2017). Melatonin can stimulate complex I and complex IV 
of the electron transport system to improve mitochondrial respiration, which can trigger 
mitochondrial transition pore and apoptosis (Leon et al., 2005). Melatonin accumulation 
transported by peptide transporter 1/2 has been shown to induce mitochondrial apoptosis in 
prostate cancer (PC3) and glioblastoma (U118) cells (Huo et al., 2017). Melatonin can stimulate 
mitochondrial differentiation and mitochondrial apoptosis through modulation of the 
mitochondrial respiratory chain that may enhance drug-induced apoptosis (Proietti et al., 2017). 
 
Figure 4: Mechanism of melatonin’s anti-breast cancer action. This schematic is taken from 
(Sardo et al., 2017), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), and 
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further modified (all modifications are expressed in red texts or arrows).  Melatonin can work 
through MT1R, MT2R (MT1/2), or receptor-independently. Activated MT1R can activate Gαi, 
which can inhibit several signaling cascades such as Ras, ERK1/2, AKT, PKCα, and AC/cAMP. 
Downstream of those signaling cascades modulates receptors (i.e., RXRα and ERα) and 
transcription factors (i.e., Myc and NF-κB), which are responsible for cell proliferation, cell 
survival, and metastasis. 
 
1.6. Mechanism of drug resistance and treatment 
Almost half of the cancer patients develop drug resistance during their lifetime (X. Wang 
et al., 2019). Cancer drug resistance can be classified into two broad categories, intrinsic and 
acquired resistance (X. Wang et al., 2019). Intrinsically-resistant patients show resistance to 
certain drug(s) before therapy, whereas, in the latter, the patient acquires the resistance against a 
drug after the treatment with that drug (X. Wang et al., 2019). Genetic modification helps BC cells 
to evade therapeutic action (Gonzalez-Angulo et al., 2007). Several mechanisms such as tumor 
mutation, upregulation of receptor activity, constitutive activation of the receptor, downregulation 
of the receptor, receptor internalization, increased efflux can play role in drug resistance 
(Gonzalez-Angulo et al., 2007). For example, multidrug resistance can occur through modulation 
of P-glycoproteins (Gonzalez-Angulo et al., 2007). Several multidrug resistance proteins such as 
MRP1, MRP2, and MRP3 can cause efflux detoxification of cancer drugs (Gonzalez-Angulo et 
al., 2007). BC cells can also express free radical scavenging enzymes to neutralize drugs, which 
work by forming free radicals (Sinha, 1989). Furthermore, BC cells can regulate apoptotic 
pathways such as MAPK, PI3K, p53 to evade cellular death signals (Gonzalez-Angulo et al., 
2007). 
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1.6.1. Anti-HER2 resistance. Several mechanisms have been proposed for trastuzumab resistance 
in HER2+ BC patients. For example, a lack of an extracellular domain in the receptor or steric 
hindrance in receptor binding can cause trastuzumab resistance (Mohamed et al., 2013). Other 
mechanisms include crosstalk with IGF-R1, activation of other HER receptors, PTEN deficiency, 
AKT mutation, and Rac1 upregulation (Mohamed et al., 2013). Lapatinib added with trastuzumab 
appears to be effective in trastuzumab-resistant patients. In a phase 3 trial, lapatinib and 
trastuzumab combination demonstrate improved progression-free survival with a 26% reduction 
in risk of death (Blackwell et al., 2010). 
1.6.2. Immune resistance. Interferons play a great role in cancer immune resistance. Three main 
types of interferons (IFN-α and IFN-β, IFN-γ, and IFN-λ) can activate JAKs and STATs through 
their respective receptors (Abril-Rodriguez & Ribas, 2017). Activation of STAT1 and STAT3 can 
induce PD-L1 expression and induce adaptive immune resistance (Abril-Rodriguez & Ribas, 
2017). Furthermore, tumors can acquire resistance through mutation of epigenetic modulation of 
the IFN- γ pathway. Loss of IFN- γ pathway sensitivity can lead to the reduction of IRF-1 
(Interferon Regulatory Factor 1) expression, apoptosis, and/or chemokines (Abril-Rodriguez & 
Ribas, 2017). Some BC exhibit de novo or acquired resistance against some antibodies (Mohamed 
et al., 2013). Many BC either is resistant or become resistant to drug therapies, which is thought 
to occur, in part, through de novo resistance, acquired resistance, or through immune escape. For 
example, many BCs keep T cell infiltration low as a defense mechanism termed as 
“immunologically cold” proposed to occur through an immunosuppressive response of nascent T 
cell response (Vonderheide et al., 2017). If this is the case, then only drugs targeted to release the 
immunosuppression, for example, drugs targeted to immunosuppressive pathways such as IDO, 
CD73, TIGIT, VISTA may be most effective in killing BC using this defense pathway. 
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(Vonderheide et al., 2017). Also, some oncogenic genes can alter chemokine production or 
increase PD-L1 production to induce immunosuppression (Vonderheide et al., 2017) and so 
understanding, specifically, the molecular mechanisms that govern the BC’s actions in the body is 
critical for effective drug therapy response in the host. 
1.6.3. Antibody Drug Conjugate resistance. Tumors can become resistant against the antibody 
portion of the antibody drug conjugate (ADC) (Collins et al., 2019). Downregulation of target 
antigen or upregulation of efflux transporter could be the possible mechanism (Collins et al., 2019). 
For example, tumors can become resistant against trastuzumab-emtansine drug conjugate by 
HER2 downregulation, increasing efflux transporter, STAT3 activation, PTEN/PI3K activation, 
and/or altered internalization (Collins et al., 2019). 
1.6.4. Tamoxifen resistance: Estrogen receptors can undergo a variety of compensatory and 
modulatory events that can impact tamoxifen’s actions against ERs (Ring & Dowsett, 2004). These 
changes can impact how ERs signal especially through its interactions with other proteins like 
IGFR, HER2, and EGFR and their downstream signaling proteins like MAPKs. For example, ERα 
can activate IGFR and its downstream ERK1/2 pathway (Kahlert et al., 2000). However, increases 
in ERK activity can induce endocrine resistance through ERK1/2-mediated phosphorylation of ER 
(Ring & Dowsett, 2004). Moreover, tamoxifen-resistant MCF-7 cells exhibit reduced ERK5 and 
pERK5 nuclear localization compared to the tamoxifen-sensitive MCF-7 cells (Wrobel et al., 
2016). HER2-transfected MCF-7 cells became tamoxifen-resistant probably through MAPK and 
by reducing co-repressors such as NCoR, SMRT (Kurokawa & Arteaga, 2001; Pietras et al., 1995). 
Loss of ER expression is the dominant mechanism of tamoxifen resistance (Ring & 
Dowsett, 2004). HDAC inhibitors prevent ER stabilization and transcribe pro-apoptotic genes and 
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thus apoptosis (Munster et al., 2011). In a phase 2 clinical trial, a combination of the HDAC 
inhibitor (vorinostat) and tamoxifen exhibit promising activity in reversing hormone resistance 
(Mohamed et al., 2013). S6 kinase 1 mTOR substrate induces ligand-independent ER activation 
by phosphorylating the activation function domain, which may cause anti-estrogen therapy 
resistance (Baselga et al., 2012). 
Modulation of co-activators and co-repressors responsible for ER signaling is another way 
to induce tamoxifen resistance. Tamoxifen resistance is shown to occur, in part, through 
attenuation of co-repressor recruitment (e.g., NCoR and SMRT) (Ali et al., 2016; Wong et al., 
2014). AIB1 (Amplified In Breast Cancer 1) co-activator expression is inversely related to disease-
free survival in tamoxifen-treated patients (C. Kent Osborne et al., 2003). Experiments show that 
SRC-1 overexpression increases the transcription of estrogen-stimulated target genes and 4-
hydroxytamoxifen agonism (Smith et al., 1997; Tzukerman et al., 1994). By contrast, the NCoR 
co-repressor exhibits low expression in tamoxifen-resistant tumors compared to the tamoxifen-
sensitive tumors in MCF-7 PDX mice (Ring & Dowsett, 2004).  
Increases in tamoxifen efflux or metabolism are other potential mechanisms for acquired 
resistance to tamoxifen. Significantly lower intra-tumor tamoxifen concentration is observed in 
acquired resistance patients, whereas the phenomenon is absent in de novo resistant patients (Ring 
& Dowsett, 2004). Women with the CYP2D6 allele variant have low plasma concentration of 
tamoxifen metabolites (Stearns et al., 2003), which indicates that increased metabolism of 
tamoxifen to ER-activating metabolites could induce resistance in BC patients (C. K. Osborne et 
al., 1991).  
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Drug therapies have also demonstrated efficacy to overcome tamoxifen resistance. For 
example, treatment with a selective CDK4/6 inhibitor (PD0332991) in TamR MCF-7 cells 
increases tamoxifen sensitivity and overcomes tamoxifen resistance (Finn et al., 2009). Also, in an 
MCF-7 tumor xenograft model, melatonin given during the hours of darkness is shown to reverse 
the tamoxifen resistance induced by light exposure at night (R. T. Dauchy et al., 2014a). A similar 
study demonstrates that circadian disruption at night (which reduces nocturnal melatonin levels) 
causes doxorubicin insensitivity in an MCF-7-PDX tumor, where replenishment with melatonin 
reestablishes the tumor’s sensitivity to doxorubicin (Xiang et al., 2015). 
 
1.7. Rationale for the development of drug conjugates for the treatment of BC 
The average cost to market for a new drug is approximately $2.5 billion (Hasan et al., 2018). 
Nonspecific target action and poor bioavailability are often the reasons for the failure of clinical 
trials in drug development (Hasan et al., 2018). Some adverse effects of anti-breast cancer drugs 
include toxicity related to bone marrow, gastrointestinal tract, nervous system, liver, urinary tract, 
heart, and lungs (Hasan et al., 2018). Moreover, breast cancer can easily develop resistance by 
dysregulating the balance of prosurvival and proapoptotic genes through mutations described 
previously (Hasan et al., 2018). Drug conjugates can be an alternative to single or combination 
therapy. It could be another viable option to treat breast cancer effectively. Drug conjugates are a 
hybrid of multiple molecules linked together either cleavable or non-cleavable linkers (Hasan et 
al., 2018). Cleavable linkers are usually stable in the circulation and break down when the 
conjugates become internalized inside the cancer cells (Hasan et al., 2018). The cleaving of the 
linker depends on the structure and target site. Chemically cleavable linkers break down under 
certain biochemical environment. For example, a hydrazine linker breaks down in the tumor acidic 
 32
environment (Ducry & Stump, 2010). Enzymatically cleavable linkers release the drugs in the 
presence of certain enzymes. For example, the valine-citrulline linker is degraded by cathepsin B 
enzyme and tends to be more stable than a hydrazine linker (Doronina et al., 2003). Drug 
conjugates can be designed to achieve the following actions (one or more) (Hasan et al., 2018): 
1. Target selectivity 
2. Reduce the bystander effect 
3. Increase cytotoxicity 
4. Increase potency 
5. Overcome drug resistance 
1.7.1. Types of drug conjugates 
At present, one antibody drug conjugate (Kadcyla®) and one nanoparticle-based drug 
conjugate (Abraxane®) has been approved for advanced metastatic breast cancer patients (Hasan 
et al., 2018). Several drug conjugates have been under investigation using different models such 
as in vitro, in-vivo, and clinical. 
1.7.1.1. Antibody-drug conjugates (ADCs) 
Most ADCs are conjugates of an antibody and a cytotoxic drug (Hasan et al., 2018). 
MylotargTM (gemtuzumab ozogamicin) was approved by the FDA in 2001 for acute myeloid 
leukemia. The trastuzumab-emtansine drug conjugate (Kadcyla®) has been approved for HER2-
positive metastatic BC, which demonstrates improved survival rate compared to the lapatinib plus 
capecitabine (Hasan et al., 2018). ADCs are usually stable in the circulation and break down at the 
target site (Rinnerthaler et al., 2019). ADCs can also show a bystander effect due to the antibody 
(Rinnerthaler et al., 2019). However, ADCs can also become resistant against BC which has been 
discussed in section 1.5. 
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1.7.1.2. Radionuclide conjugates 
A targeted drug delivery system is used to deliver a cytotoxic radionuclide to the tumor. 
The chelation method can be used to conjugate a radionuclide to a monoclonal antibody (Hasan et 
al., 2018). For example, 89Zr-trastuzumab-monomethyl auristatin E immunoconjugate 
demonstrates more than 90% tumor volume reduction after 20 days of treatment in a HER2-
positive murine model (Adumeau et al., 2018). 
1.7.1.3. Drug-delivery system conjugates 
Similar to radionuclide conjugates, a drug delivery system can be used to deliver cytotoxic 
drugs to the tumor. The drug delivery system is selected based on the status of the target tissue. 
For example, the FDA approved Abraxane (Paclitaxel conjugated with albumin-bound 
nanoparticles) can be categorized into this group (Hasan et al., 2018). 
1.7.1.4. Drug-drug conjugates 
Several drug-drug conjugates are being tested in BC cells and patient-derived xenograft 
(PDX) models (Hasan et al., 2018). Multiple drugs can be used to make conjugates. For example, 
platinum-, acridine-, endoxifen-containing drug conjugates exhibit higher toxicity compared to a 
cisplatin and tamoxifen combination therapy (Ding et al., 2013). 
1.7.2. Pharmacology of drug conjugates 
Two or more drug moieties can be linked with a cleavable or non-cleavable linker. The 
pharmacological property of a drug conjugate depends on both drug moieties and linkers. Drug 
conjugates can demonstrate higher potency or cytotoxicity compared to the individual component. 
For example, ribociclib-vorinostat conjugate exhibit higher potency (IC50 = 1.86 µmol/L) 
compared to vorinostat (IC50 = 2.56 µmol/L) and ribociclib (IC50 > 10 µmol/L) in MDA-MB-231 
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TNBC cell line (Li et al., 2018). Moreover, tamoxifen-vorinostat conjugates exhibit higher toxicity 
in MCF-7 and MDA-MB-231 compared to the tamoxifen or vorinostat alone (Gryder et al., 2013). 
1.7.3. Pharmacokinetics of drug conjugates 
Pharmacokinetic data can help in understanding the deconjugation process, as well as the 
metabolism of the conjugate. Pharmacokinetic parameters (i.e. clearance, half-life, and 
distribution) of ADCs depend on the drug components and/or linkers (Kamath & Iyer, 2015). 
Clearance may depend on the stability of the linkers. For example, the disulfide linker 
demonstrates faster clearance compared to the nonreducible MCC linker in female beige nude 
mice (Lewis Phillips et al., 2008). A drug conjugate can alter the half-life and tumor tissue 
distribution. For example, paclitaxel linked with poly-L-glutamic acid demonstrates a half-life of 
100 hours and a low volume of distribution (Bumbaca et al., 2019). Abraxane® (albumin-bound 
paclitaxel nanoparticle) exhibits higher paclitaxel plasma concentration compared to the solvent-
based paclitaxel (Bumbaca et al., 2019). 
1.7.4. Models for drug conjugates studies 
Choosing the right model for studying drug conjugates depends on several factors like the 
types of conjugate being assessed, the conjugate’s target, and the expected outcomes. Therefore, 
it is critical to choose the appropriate model for analysis, which may be through the use of in vitro 
cell culture models, in vivo rodent models and, if possible, clinical models. For this dissertation, 
in vitro breast cancer cell models were chosen because all, except for the mouse mammary 
carcinoma cells (MMCs), were derived from human tumors. A brief discussion on different BC 
models is described below. A more detailed description of the cell models used in this study can 
be found under Section 2.1. 
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1.7.4.1. In vitro 
Due to the complexity and heterogeneity of BC, several BC cell lines have been developed 
for drug development research. One way to classify the cell lines is based on receptor expression. 
The ER+/PR+ cell line, MCF-7, is the most widely used BC cell line to study endocrine or anti-
estrogen therapy (Holliday & Speirs, 2011). MCF-7 cells were derived from the pleural effusion 
of a metastatic BC patient (Levenson & Jordan, 1997). The mouse mammary carcinoma (MMC) 
cell line (ER–/PR–/HER2+) was obtained from a spontaneous tumor harvested from the neu-
transgenic mice. It is similar to human BC in that its hormonal profile mimics that of 
premenopausal BC in humans (Dodda et al., 2019). TNBC cell lines although devoid of ER, PR, 
and HER2 receptors are not the same but, rather, heterogeneous in nature (Foulkes et al., 2010). 
TNBCs can arise due to different mutations (i.e., BRCA, PTEN, and p53) or different levels of 
receptor expression (i.e., TGF and EGFR) (Foulkes et al., 2010). This is important to know 
especially when deducing the molecular mechanisms underlying novel BC drugs like the 
melatonin-tamoxifen drug conjugates described in this dissertation. Some widely used TNBC cell 
lines include: MDA-MB-231, MDA-MB-468, BT-20, and BT-549 (Chavez et al., 2010). 
1.7.4.2. In vivo 
In vivo or preclinical models are vital to drug development because of the ethical 
considerations for testing candidate drugs in humans. Animal testing can give information about 
the efficacy, toxicity, and pharmacokinetic profiles of candidate drugs (Mak et al., 2014). Also, 
the FDA mandates the completion of a preclinical trial for a new drug molecule before it can move 
into the clinical phase (Mak et al., 2014). Since there are different ways to study the anti-cancer 
actions of drugs using animal models, the first concern is to determine the suitability of the in vivo 
model. 
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1. Xenograft: These models are popular in that they are tumors or cells obtained from 
BC patients or commercially purchased. These tumors or cells are implanted in 
animals (mostly rodents) either orthotopically or in different organs other than the 
mammary tissue. Patient-derived xenograft (PDX) models are a suitable model to 
study tumor heterogeneity since the patient’s characteristics can be maintained in the 
tumor (Whittle et al., 2015). However, one limitation to using this type of model is 
that the animal needs to be immunocompromised to prevent tumor rejection, which 
does not mimic the patient’s immune system (Whittle et al., 2015). 
2. Carcinogen induced: In this model, radiation or chemicals (i.e. 7,12-
dimethylbenz[a]-anthracene, methylcholanthrene, and urethane) are used to induce 
BC in rodents (Imaoka et al., 2009). This type of model is not as widely used since 
most human cancer occurs from spontaneous mutations. 
3. Genetically- induced: Transposon based, transgenic, knock-in, knockout, and 
inducible mutation animals have been widely used for genetic research and to induce 
BC (Swiatnicki & Andrechek, 2019). There are about 100 oncogenes that have been 
targeted to induce carcinogenesis (Allred & Medina, 2008). Overexpression of 
oncogenes such as c-myc, ras, and HER2 can induce mammary cell proliferation and 
form tumors (Swiatnicki & Andrechek, 2019). These types of models are commonly 
used in BC research. 
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Chapter 2: Research Objectives 
2.1. Rationale 
Drug conjugates show promise as novel anti-cancer agents as reviewed (Hasan et al., 
2018). It is thought that the conjugated form of multiple drugs may exhibit beneficial effects based 
on diverse targets such as receptors or intracellular signaling proteins (Hasan et al., 2018). In 
keeping with this idea, melatonin-tamoxifen drug conjugates were developed with varying CH2-
spacer lengths as novel BC drugs since both melatonin and tamoxifen alone or in combination but 
unlinked are effective anti-cancer agents (Hasan et al., 2018). A melatonin-tamoxifen drug 
conjugate with a spacer length of five CH2-groups (C5) was reported as a promising new class of 
drugs for the prevention and treatment of BC without uterotropic effects (P.A. Witt-Enderby et al., 
2014), US Patent 8,785,501). To further assess the influence of this class of drugs, melatonin-
tamoxifen drug conjugates with varying spacer lengths were synthesized and consist of C2 
(contains two CH2 spacer groups; shortest spacer), C4 (contains four CH2 spacer groups), C5 
(contains five CH2 spacer groups), C9 (contains nine CH2 spacer groups) and C15 (contains fifteen 
CH2 spacer groups; longest spacers) (Figure 5). In this study, these five melatonin and tamoxifen 
drug conjugates (C2, C4, C5, C9, and C15) were tested against BC cells that are ER-positive 
(MCF-7), ER-positive but tamoxifen-resistant MCF-7 (TamR MCF-7), HER2 positive (MMC), 
triple-negative (MDA-MB-231 and BT-549), and patient-derived xenograft cells and tissue. These 
cell lines and models were chosen because melatonin, tamoxifen, and melatonin plus tamoxifen 
have demonstrated anti-cancer actions against these types of breast cancers (Hasan et al., 2019). 
The MCF-7 cell line was derived from a metastatic pleural effusion from a 69-year old 
Caucasian female with an adenoma of the breast classified as epithelial and adherent. 
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The MMC (ER-/PR-/HER2+) cell line was derived from the breast tumor tissue of Neu 
mice expressing Neu proto-oncogene. Neu-transgenic mice [strain name, FVB/N-TgN 
(MMTVneu)-202Mul] were obtained from Charles River Laboratory (Bar Harbor, ME). These 
mice harbor a nonmutated, nonactivated rat neu under the control of the mouse mammary tumor 
virus (MMTV) promoter. This model is parallel to human HER2/neu-overexpressing cancer in a 
number of ways. First, the expression of neu under the mouse mammary tumor virus promoter 
results in an amplified expression in the breast epithelium. This is analogous to gene amplification 
in humans that results in overexpression of the nonmutated HER-2/neu with a significant 
proportion of cases expressing medium to high levels of the protein. 
 Based on our proposed mechanism of action, we have selected two TNBC cell lines 
expressing different mutations. The MDA-MB-231 cell line was derived from the metastatic 
pleural effusion of a 51-year old Caucasian female with an adenocarcinoma of the breast, classified 
as basal B/claudin-low (Chavez et al., 2010). It contains a p53 mutation, KRAS mutation, and wild 
type BRCA 1 (Chavez et al., 2010). These cells are epithelial, adherent, and display a triple-
negative hormonal profile. Capable of forming tumors in both nude and ALS-treated BALB/c 
mice, the MDA-MB-231 cells are hypotriploid with a modal chromosome number of 65. The BT-
549 cell line was derived from a metastatic primary tumor of a 72-year old Caucasian female 
classified as basal B/claudin-low (Chavez et al., 2010). It contains PTEN homo deletion, p53 
mutation, and wild type BRCA1 (Chavez et al., 2010). These cells are triple-negative, 
polymorphic, adherent, and epithelial in nature. BT-549 cells are multinucleated giant cells with a 
modal number of 78. 
C4 and C5 were also tested in patient-derived xenograft cells and tumors. PDX cells and 
PDX mice tissues were derived from chemo-naive and chemoresistant triple-negative BC patients. 
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TU-BcX-4IC cells, which were chemonaive, were derived from a mastectomy specimen of a 
Caucasian female. The TU-BcX-4IC tumor was a metaplastic breast carcinoma that had a TNBC 
PAM50 subtype. TU-BcX-4QAN PDX tumor was established from a mastectomy specimen of an 
African American woman and represents a drug-resistant TNBC tumor. The PDX tumor was 
propagated and maintained in SCID/Beige immunodeficient mice (CB17.cg-PrkdcscidLystbg/Crl) 
obtained from Charles River (Wilmington, MA, USA). 
MEK1/2, MEK5, and PI3K were chosen due to their role in BC pathogenesis and 
MT1R/ESR1-mediated BC signaling (Driggers & Segars, 2002; Lobenhofer et al., 2000). Estrogen, 
through ERs, can produce MCF-7 cell mitogenesis via MAPK and PI3K (Driggers & Segars, 2002; 
Lobenhofer et al., 2000). Melatonin works through MEK1/2 to promote differentiation processes 
that may be protective against BC (Radio et al., 2006; Sethi et al., 2010a). Mutations in the 
PI3K/Akt signaling pathway correlate with ER+ or ER+/PR+ BC where ~30% of ER+ BC patients 
have the PI3KCA mutation  while the AKT1 mutation was found exclusively in ER+/PR+ BC 
(Araki & Miyoshi, 2018). Also, melatonin has been shown to inhibit cell survival, proliferation by 
suppressing phosphorylation of the PI3K/Akt pathway (J. Wang et al., 2012). 
 
2.2. Hypothesis 
Melatonin-tamoxifen drug conjugates will exhibit anti-cancer effects (reduced cell 




2.3. Specific Aims 
The study was designed to test all melatonin-tamoxifen drug conjugates (C2, C4, C5, C9, C15) 
on MCF-7, MMC, MDA-MB-231, BT-549 BC cell lines in terms of cell viability, cell migration, 
and binding affinities to ERs and MT1Rs. Based on the outcomes, two drug conjugates were 
selected for further evaluation in TamR MCF-7 cells and patient-derived xenograft cells (chemo-
naïve) and tumors (chemo-resistant). Next, different pharmacokinetic parameters (i.e., clearance, 
half-life, and bioavailability) were assessed using the female mice model. The research was 
conducted based on the following specific aims: 
i. To assess the anti-cancer actions (inhibition of cell viability and cell migration) of 
melatonin-tamoxifen drug conjugates (C2, C4, C5, C9, C15) on MCF-7, MMC, MDA-
MB-231, and BT-549 cell lines. 
ii. To assess the binding affinities of melatonin-tamoxifen drug conjugates (C2, C4, C5, C9, 
C15) to ERs and MT1Rs. 
iii. To assess the role of melatonin-tamoxifen drug conjugates (C4, C5) on TamR MCF-7 
cells and in patient-derived TNBC (chemonaive or chemoresistant) xenografts. 
iv. To assess the role of MEK1/2, MEK5, and PI3 kinases in mediating C4 and C5 
melatonin-tamoxifen drug conjugates’ anti-cancer actions (i.e., viability and migration) 
in MCF-7, MMC and TNBC cells. 
v. To assess the effect of C4 and C5 melatonin-tamoxifen drug conjugates on pERK5, 
pERK1/2, pAKT, NF-κB, RUNX2, and β1-INTEGRIN protein levels. 
vi. To assess the metabolism of C4 and C5 melatonin-tamoxifen drug conjugates both in 
vitro and in vivo. 
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Chapter 3: Materials and Methods 
3.1. Synthesis of melatonin-tamoxifen drug conjugates 
All of the synthesis studies were conducted by Dr. Zlotos and his research lab. For a 
complete description and analysis of these compounds, please refer to (Hasan et al. Mol Pharm 
Paper). (Hasan et al., 2018). In brief, melatonin-tamoxifen drug conjugates were developed with 
varying CH2-spacer lengths: C2, which contains two CH2 spacer groups, is the shortest spacer; C4 
contains four CH2 spacer groups; C5 contains five CH2 spacer groups; C9 contains nine CH2 spacer 
groups; and C15, contains fifteen CH2 spacer groups, contains the longest spacer (Figure 5). 
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n = 2, 4, 5, 9, 15
MeO2C(CH2)n
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C2         2
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C9         9
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n
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3.2. Competition binding for melatonin and estrogen receptors 
Binding affinities of each of the drug conjugates (C2, C4, C5, C9, and C15) or melatonin, 
tamoxifen, 4-OH-tamoxifen alone were measured using 2-[125I]-iodomelatonin, [125I]-estradiol and 
[3H]-estradiol respectively, as described previously with modification (Kirker et al., 2013; P. A. 
Witt-Enderby & Dubocovich, 1996). In brief, the experiments were conducted on mouse uterus 
((P.A. Witt-Enderby et al., 2014); US Patent 8,785,501) and in whole-cell lysates prepared from 
human MT1 CHO cells or MCF-7 breast cancer cells grown to confluence on 10cm plates. Cell 
lysates were prepared by first washing cells with 5 mL of PBS and then lifting them into the buffer 
(10 mM KPO4, 1 mM EDTA, pH 7.4). Cells were then pelleted by centrifugation (277 x g for 5 
min) and then resuspended in Tris-HCl buffer (50 mM, pH 7.4). Next, cells were added to tubes 
containing 115 pM of 2-[125I]-iodomelatonin (Perkin-Elmer, 2200 Ci/mmole) in the presence of 
melatonin (1 pM-100 µM) or drug conjugate (1 pM-100 µM) or the absence of melatonin or drug 
conjugated (total binding). For 4-OH-tamoxifen or drug conjugate binding in MCF-7 cells, 2 nM 
of [3H]-estradiol was used in the presence of 4-OH-tamoxifen (1 pM-100 µM) or drug conjugate 
(1 pM-100 µM). The incubation volume was 260 µL. Next, cells were incubated for one hr at room 
temperature and then terminated by the addition of ice-cold 50 mM Tris-HCl solution and rapid 
filtration over glass-fiber filters (0.22 μm; Schleicher & Schuell, Keene, NH) presoaked in 0.5% 
polyethyleneimine solution (v/v) (Sigma Aldrich, St. Louis, MO). Each filter was washed twice 
with 5 mL of cold buffer. Radioactivity of [125I]-iodomelatonin and [3H]-estradiol were determined 
in a gamma counter and scintillation counter respectively. 
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3.3. Total binding assay 
 G-protein coupled estrogen receptor (GPR30) total binding to C4 and C5 in MCF-7 cells 
was assessed using [3H]-estradiol as described with modification (Kirker et al., 2013) on MCF-7 
cell lysates. Briefly, 200 μL of cell lysate was added to tubes containing 3 nM of [3H]-estradiol 
(Perkin Elmer, Waltham, MA, USA) in the absence (total binding) or presence of 10 μM 4-OH-
tamoxifen, 1 μM C4, 1 μM C5 and/or 1 μM G1 GPR30 agonist (Cayman Chemical Company, Ann 
Arbor, MI). The whole incubation volume was 260 µL. Binding data, initially expressed as 
moles/mg protein, were repeated three times and subjected to one-way ANOVA. 
 
3.4. Cell culture 
MCF-7, MMC, MDA-MB-231, and BT-549 cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA), were cultured in DMEM:F12 containing 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin at 37° C in a humidified atmosphere with 5% 
CO2. BT-549 cells were cultured in the same condition (10% FBS and 1% penicillin/streptomycin 
at 37° C in a humidified atmosphere with 5% CO2) using RPMI-1640 medium. 
 
3.5. Development and characterization of TamR MCF-7 cells 
The characterization of TamR MCF-7 cells is described in Figure 12. In brief, MCF-7 cells, 
obtained from ATCC, were cultured at 37° C in a humidified atmosphere with 5% CO2 for 6 
months in DMEM (phenol red-free):F-12 containing 10% charcoal-stripped FBS and 1% 
penicillin/streptomycin and 100 nM 4-OH-tamoxifen; 6 mo was the amount of time required for 
MCF-7 cells to become resistant to tamoxifen. For growth assays, WT (wild type) and TamR 
MCF-7 cells were counted using trypan blue exclusion assay following exposure to 100 nM 4-
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OH-tamoxifen for 1-7 days. For immunocytochemistry images, MCF-7 and TamR cells were 
treated with either vehicle or 100 nM 4-Hydroxytamoxifen for 24 hr. After treatment, cells were 
fixed in 4% Paraformaldehyde for 15 min. Cells were then permeabilized with 0.3% Triton-X 
followed by the addition of rabbit Ki-67 (1:1000, CAT# 9129S, Cell Signaling Technology, 
Danvers, MA) and mouse ∝-Tubulin (1:1000, CAT# 3873S, Cell Signaling Technology, Danvers, 
MA) primary antibodies. Goat anti-mouse Alexa Fluor 488 nm (1:1000, CAT# A-11001, Life 
Technologies, Carlsbad, CA) and goat anti-Rabbit Alexa Fluor 555 nm (1:1000, CAT# A-21429, 
Life Technologies, Carlsbad, CA) were used as secondary antibodies. A Hoechst (Fisher) stain 
was used to visualize the nucleus. Images were obtained with the EVOS fluorescent inverted 
microscope (Life Technologies, Carlsbad, CA) under 20x objective. Scale bar = 200 microns. 
Basal expression of pERK5, pERK1/2, ER-α, NF-κB, and pAKT in TamR MCF-7 and MCF-7 
cells were measured by western blot. Bands were quantified using Image Studio™ Lite Software 
(LI-COR Biosciences, Lincoln, NE) and normalized against β-actin (see western blot methods 
section for further detail). 
 
3.6. Ex vivo treatment of PDX tumors 
TU-BcX-4QAN PDX tumor was established from a mastectomy specimen of an African 
American woman and represents a drug-resistant TNBC tumor. The PDX tumor was propagated 
and maintained in SCID/Beige immunodeficient mice (CB17.cg-PrkdcscidLystbg/Crl) obtained 
from Charles River (Wilmington, MA, USA). After two serial transplantation passages in mice, 
the tumor was removed, and small tumor pieces were dissected (approximately 3 x 3 mm2). The 
tumor pieces were kept intact and placed in individual wells of a 24-well plate. Drug solutions of 
DMSO/PBS vehicle control, melatonin (10 µM), tamoxifen (10 µM), melatonin + tamoxifen (10 
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µM of each), C4 (10 µM), and C5 (10 µM) were made and added to the intact tumor pieces (1 mL 
per well) in triplicate. After 24 hr of incubation at 37° C in 5% CO2, tumor pieces were removed 
and placed in 1.5 mL centrifuge tubes and stored at -20° C. 
 
3.7. In vitro treatment of PDX-derived cells for western blot 
TU-BcX-4IC cells were derived from a mastectomy specimen of a Caucasian female. The 
TU-BcX-4IC tumor was a metaplastic breast carcinoma that had a TNBC PAM50 subtype. The 
cells were maintained in DMEM supplemented with 10% FBS, insulin, non-essential amino acids, 
minimal essential amino acids, antibiotic-antimycotic, and sodium pyruvate at 37° C in 5% CO2. 
TU-BcX-4IC cells were plated in T-25 flasks and exposed to serum-free media for 24 hr before 
treatment. DMSO/PBS vehicle control, melatonin (10 µM), tamoxifen (10 µM), melatonin + 
tamoxifen (10 µM of each), C4 (10 µM), and C5 (10 µM) were added to the cells in triplicate. 
After 36 hr, of incubation at 37° C in 5% CO2, images were obtained using brightfield microscopy 
(40x magnification) and cells were harvested. Adherent cells were harvested from the DMSO and 
melatonin treatments. Detached cells were harvested in the media from the tamoxifen, 
melatonin+tamoxifen, C4, and C5 treatments. 
 
3.8. Cell viability 
The MTT assay method was used to determine cellular viability following exposure to each 
of the drug conjugates (C2, C4, C5, C9, C15. Sub-confluent monolayer cell lines grown on 10 cm 
culture plates were trypsinized and plated equally into each well of a 48-well plate. The next day, 
cells were exposed to each of the drug conjugates (1 pM, 1 nM, 1 µM, 10 µM, and, 100 µM) alone 
or in combination with the inhibitors for 24 hr. For the inhibitor studies assessing the involvement 
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of MEK1/2, MEK5 or PI3 kinase, PD98059 (Santa Cruz Biotechnology, Dallas, TX), Bix02189 
(Santa Cruz Biotechnology, Dallas, TX) and pictilisib (PI3 kinase inhibitor, SellerChem, Houston, 
TX, USA) were all added at a final concentration of 10 µM. Melatonin (1 pM, 1 nM, 1 µM, 10 
µM, and, 100 µM; Millipore Sigma, Burlington, MA, USA), tamoxifen alone or in combination 
with melatonin (1 pM, 1 nM, 1 µM, 10 µM, and, 100 µM; Millipore Sigma, Burlington, MA, 
USA), 4-OH-tamoxifen alone or in combination with melatonin (1 pM, 1 nM, 1 µM, 10 µM, and, 
100 µM; Millipore Sigma, Burlington, MA, USA) were used as control groups. After 24 hr, 25 µL 
MTT (Sigma-Aldrich, St. Louis, MO) (dissolved in sterile water) (5mg/mL) was added to each 
well (0.5 mg/mL final concentration), and the plates were placed in the incubator for 3 hr (5% CO2 
and 37º C). Next, the plates were centrifuged at 50 x g (37º C for 5 min). The entire medium was 
aspirated, and 250 µL DMSO (Fisher Scientific, Pittsburgh, PA) was added to each well to stop 
the reaction. The plate was wrapped in aluminum foil and incubated at room temperature for 15 
min to dissolve the MTT-formazan crystals. The absorbance was measured at 570 nm (VICTOR3 
1420 multilabel counter, Perkin Elmer). 
 
3.9. Cell Migration 
Wound/scratch assays were performed in 24-well cell plates to determine the invasiveness 
of the cells following exposure to each of the drug conjugates (C2, C4, C5, C9, and C15). Cells 
were plated and allowed to settle for 24 hr. After 24 hr, a border was created using a 200 μL pipette 
tip that was dragged across the bottom of each well to make a visible and uniform space between 
the cells. The floating cells were aspirated, and the cells were refed fresh media containing the 
various drug treatments described for the MTT assays above. The border width was measured at 
baseline (time 0 hr) and then 24 hr following exposure to the treatments (time 24 hr) added alone 
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or in combination with the inhibitors (where indicated) using an EVOS digital inverted 
fluorescence microscope. Any width changes were expressed as percentages. For the inhibitor 
studies assessing the involvement of MEK1/2, MEK5 or PI3 kinase, PD98059, Bix02189 and 
pictilisib were all added at a final concentration of 10 µM. Border widths were calculated as (24 
hr-0 hr) / 0 hr x 100; where a more positive number indicates inhibition of migration while a more 
negative number indicates stimulation of migration. For calculating the max inhibition of TamR 
MCF-7 cell migration, percent change in border width was normalized against minimum inhibition 
of migration, whereas minimum inhibition of migration was considered as 0% and no border 
change was considered as 100%. 
 
3.10. Western blot 
To identify potential intracellular targets, C4- or C5-mediated effects on pERK1/2, pERK5, 
p-AKT, NF-ĸB, Runx2, and β1-integrin proteins were analyzed by western blot analysis. BC cells 
were treated with each drug conjugate (1 nM and 10 µM) in the absence or presence of 10 µM of 
PD98059, BIX02189 or pictilisib 0 min (baseline) or 15 min after which the cells were scraped 
into Laemmli sample buffer containing β-mercaptoethanol, heated for 5 min at 95o C, cooled and 
then stored at -20o C until use. Western blot analysis was conducted using the Odyssey® Western 
Blotting Kit IV RD (CAT# 926-31084, LI-COR Bioscience, USA). Equal amounts of each sample 
(20 µL) and 5 µL of molecular weight marker (Precision Plus ProteinTM, CAT# 161-0373, BioRad, 
USA) were loaded onto 10% gels. Proteins, separated by SDS-PAGE, were transferred to 
nitrocellulose membranes. Membranes were then incubated in blocking buffer (LI-COR 
Biosciences, Lincoln, NE) for 30 min and then incubated with each respective primary antibody 
[(rabbit anti-pERK1/2 and anti-pERK5 (T218/Y220; CAT# 3371, 1:1000 dilution, Cell Signaling, 
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Danvers, MA), rabbit anti-phospho-AKT (CAT# 9271, 1:750 dilution; Cell Signaling, Danvers, 
MA), rabbit anti-NF-ĸB (p52, CAT# sc-298; 1:1000 dilution; Santa Cruz, Dallas, TX), rabbit anti-
Runx2 (CAT# sc-10758; 1:1000 dilution; Santa Cruz, Dallas, TX), rat ER-α (CAT# sc-53493; 
1:750 dilution; Santa Cruz, Dallas, TX) and rabbit anti-β1-integrin (M-106; CAT# sc-8978; 1:1000 
dilution; Santa Cruz, Dallas, TX)] along with mouse anti-β-actin (CAT# 926-42212, LI-COR 
Biosciences, USA) overnight at 4° C. Next, the blots were washed with PBS containing Tween-
20 and then incubated with secondary antibodies [goat anti-rabbit (IRDye 800CW, CAT# 925-
32211, 1:20,000 dilution; LI-COR Biosciences) and goat anti-mouse (IRDye 680RD, CAT# 925-
68070, 1:20,000 dilution; LI-COR Biosciences)] for 30min at room temperature. For ER-α primary 
antibody, goat anti-rat (IRDye 800CW, CAT# 925-32219, 1:20,000 dilution; LI-COR 
Biosciences) was used for 30 min at room temperature. Bands were quantified using Image 
Studio™ Lite (LI-COR Biosciences, Lincoln, NE, USA) software and normalized against β-actin 
to control for differences in protein loading between treatment groups. 
 
3.11. Microsomal incubation method 
Human liver microsomes (UltrapoolTM HLM 150, Cat#452117, Corning, Woburn, MA, 
USA) and mouse liver microsomes (pooled female MLM, Cat#452702, Corning, Woburn, MA, 
USA) were used to assess susceptibility to hepatic metabolism of C4 and C5. Specifically, 
microsomes were incubated with 5 µM of either C4, C5, or tamoxifen in the presence of an 
NADPH regenerating system (0.5 mM NADPH, 1 unit/mL glucose-6-phosphate dehydrogenase, 
and 10 mM glucose 6-phosphate) at 37° C for 0, 5, and 10 min in mouse, and 0, 10, and 20 min in 
human microsomes. A longer incubation time was required for human microsomes compared to 
mouse microsomes because of slow metabolism. Reactions were stopped and precipitated using 
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50% acetonitrile. Reaction vials were centrifuged at 9500 x g (4º C for 15 min) The rate of drug 
loss was measured by HPLC-UV detection. Following optimization of the HPLC conditions 
[column pre-wash 2 min with 70% solvent A (10% methanol in phosphate buffer) and 30% solvent 
B (100% methanol) for 2 min; sample runs = 25 min at a gradient flow rate of 0.4mL/min where 
solvent B was changed from 30% to 90%], retention times for C4 (retention time = 20.46 min) and 
C5 (retention time = 20.93 min) were similar to that of tamoxifen (retention time = 20.46 min). 
Peak absorbance of each sample was normalized against the internal standard, celecoxib. 
Celecoxib was used as an internal standard for this study because it gave a retention time (RT = 
11.51 min) distinguishable from the retention times for tamoxifen, C4, and C5 melatonin-
tamoxifen drug conjugates. 
 
3.12. Pharmacokinetic analysis of C4 and C5 
All original studies using animals have been carried out in accordance with the Guide for 
the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National 
Institutes of Health, and were approved by the Institution’s Animal Care and Use Committee or 
local equivalent (IACUC approval number: 1607-07M1). C57BL/6J female mice (2 months) were 
used to assess the pharmacokinetic properties of C4 and C5. The drugs were initially dissolved in 
ethanol (5% v/v) and then added to hydroxypropyl methylcellulose (5 mg/mL in ddH20) to obtain 
a final concentration of 0.5% (w/v). The C4 and C5, each was administered separately by two 
routes of administration—subcutaneous and oral. The outcomes were compared to the 
subcutaneous administration of tamoxifen, which served as the control group. One group of mice 
(n=8) received a subcutaneous dose of 1 mg/kg body weight while another group received an oral 
dose of 10 mg/kg body weight. Different doses for the two routes were given to achieve similar 
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exposures for the two routes based on experience with tamoxifen (Reid et al., 2014). For both 
routes of administration, blood was collected at similar time points (0, 30, 60, 120, 180, 360, 480, 
and 1440 min) except that one earlier time of 15min was also taken for the subcutaneous route. 
One C56BL/6J female mouse age of 2 months was used for each time point. The blood was 
collected in a K2-EDTA coated tube by decapitation after CO2 euthanasia. After that, blood was 
centrifuged at 1166 x g (4º C for 5 min) to separate the plasma. The plasma was then stored at -
80º C until performing the LC-MS. 
 
3.13. LC-MS/MS method for quantification of tamoxifen, C4, and C5 in mouse 
plasma 
Deuterated tamoxifen (TAM -d5) was purchased from Toronto Research Chemicals, 
Canada. Mouse plasma in Li- Heparin was purchased from Lampire biological laboratories, USA. 
Acetonitrile (HPLC grade), isopropanol, hexane, and formic acid (MS Grade) were purchased 
from Fisher Chemicals, USA. Individual stock solutions (20 µg/mL) of tamoxifen, C4, and C5 
were prepared in methanol and stored at -20 C until use. The standards for the calibration curve 
were prepared by serial dilution of working stock solutions (64 ng/mL) of tamoxifen, C4, and C5 
in methanol and then dividing them into 125 µL aliquots. Deuterated tamoxifen (TAM-d5) was 
used as the internal standard. Working stock solutions (50 ng/mL) of TAM-d5 were prepared in 
methanol, divided into 20 µL aliquots, and stored at -20 C until use. 
Calibration standards (0.25, 0.5, 1, 2, 4, 8, 16, and, 32 ng/mL) of tamoxifen, C4 or C5 were 
prepared in 115 µL of mouse plasma and then spiked with TAM-d5 (2 ng/mL final concentration) 
to quantify all the compounds during the extraction process. Quality control (QC) samples of 0.1 
ng/mL (Lower Limit of Quantification, LLQ), 2 ng/mL (QC-Low), and 32 ng/mL (QC- high) were 
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run in parallel and in triplicate for each experimental run of tamoxifen, C4, and C5. Before the 
extraction process, 10 µL of 1 M NaOH was added to 200 µL of each sample followed by vortexing 
for 30 s. Next, 1000 µL of extraction solvent [hexane:isopropanol (95:5, v/v)] was added to each 
tube and then placed on a rotary shaker for 5 min. Samples were then centrifuged for 5 min at 9500 
x g to separate the aqueous phase (bottom layer) from the organic phase (top layer). Next, 900 µL 
of the supernatant was transferred to a clean test tube. The remaining aqueous layer in the original 
tube was subjected to the same extraction process by adding another 1000 µL of extraction solvent. 
The total transferred supernatant (organic phase) was air dried under N2 flux. The dry residue was 
dissolved in 200 µL of methanol and subjected to liquid chromatography with mass spectrometry 
detection (LC-MS). 
HPLC followed by tandem mass spectrometry was conducted using a system model 1200 
and triple quadrupole mass spectrometer (model 6460) with a jet stream electrospray ion (ESI) 
source (Agilent Technologies, Santa Clara, CA). Data acquisition and chromatographic peak 
integration were performed using Agilent MassHunter software (versions B02.01 and B02.00). All 
analyses were performed in positive ion mode and chromatograms were recorded in multiple 
reaction monitoring (MRM) scan mode. Mass spectrometry collision parameters for tamoxifen, 
TAM-d5, C4, and C5 are shown in Table 1, while mass spectrometry acquisition and source 
parameters for the instrument are summarized in Table 2. 
Chromatographic separation was achieved with a Thermo scientific Hypersil GOLDTM; 
ThermoScientific, Waltham, MA) reverse phase C18 column (50 x 4.6 mm, 3 µm packing) 
thermostated at T = 25 C. Deionized water and acetonitrile, both acidified with 0.1% formic acid, 
were used as mobile phase A and B, respectively, at the flow rate of 0.5 mL/min. A linear gradient 
separation was used where mobile phase B was initially set at 20% for 1min, then increased to 
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80% over 5 min, and then further increased to 95% over 0.1 min where it remained for 1.9 min. 
Next, mobile phase B was decreased to initial conditions over 0.1 min, and the system was re-
equilibrated for 3.9 min before the following injection. The total run time was 12 min with an 
injection volume of 40 µL. The injection needle was washed in between analyses using a wash 
solution of acetonitrile containing 0.1% formic acid (v/v) for 20 s. The needle draw and ejection 
speed was set to 100 µL/min. 
Calibration samples and quality control samples (described above and performed in 
triplicate) were used for the determination of linearity, accuracy, and precision. Calibration curves 
were plotted by correlating the peak area ratio of each compound (relative to TAM-d5 as the 
internal standard) as a function of the concentration of spiked standard solutions with a weight 
factor of 1/y2 or 1/relative response2. The concentration range (0.25 ng/mL-32 ng/mL with LLQ 
of 0.1 ng/mL) for the calibration standards was chosen based on the level of concentration expected 
in the unknown samples. The concentration of the quality control samples was set to 0.1 ng/mL 
(LLQ), 2 ng/mL (QC-low), and 32 ng/mL (QC-high) for tamoxifen, C4, and C5 based on the range 
of calibration concentrations for each compound. 
Middle concentrations of the calibration curve were used to determine matrix effects and 
extraction recovery. The matrix effect was determined by comparing the peak area in post-
extracted spiked samples versus the peak area in a standard methanol solution. At least six 
independent plasma samples with different concentrations were tested for the matrix effect for 
each compound. The extraction recovery was calculated by comparing the peak area of each 
extracted sample (spiked standard in the blank matrix) with the post-extracted spiked sample at 
the same concentration; this represented 100% recovery. Recovery was calculated for at least 4 
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independent plasma samples with different concentrations for each compound. Matrix effects and 
extraction recoveries for tamoxifen, C4, and C5 are shown in Table 3. 
Table 1: Mass Spectrometry Collision Parameters 
Compounds Parent (m/z) Daughter (m/z) Collision Energy (V) 
Tamoxifen (TAM) 372.2 72.1 21 
TAM-d5 377.2 72.1 21 
C4 630.4 174.1 45 
C5 644.4 174.1 45 
 
Table 2: Mass Spectrometry Acquisition and Source Parameters 
Source parameters Conditions Acquisition parameters Conditions 
Gas Temperature 320 C Dwell time 200 ms 
Gas Flow 10 l/min Fragmentor Voltage 135 V 
Nebulizer 45 psi Cell Accelerator Voltage 7 V 
Sheath gas Temp  370 C Polarity  positive 
Sheath gas Flow 11 l/min   
Capillary Voltage 3500 V   












Table 3: Matrix Effect and Extraction Recovery (a n = 7, b n = 6, c n = 4) 
Compounds Matrix effect (%) 
Mean  SD 
Extraction Recovery (%) 
Mean SD 
Tamoxifen 10.75  7.76 a 94.34  14.41 a 
C4 8.47  8.64 a 96.9  29.92 a 
C5 11.32  6.85 b 105.27  6.18 c 
 
3.14. Statistical analysis 
 All statistical analyses were performed using GraphPad Prism™ (version 6; GraphPad 
Software, La Jolla, CA) and determined in advance. Data represent the mean ± SD unless 
mentioned otherwise. Data points that were determined to be outliers by Grubbs’ test were 
excluded. The mean IC50 values of cell viability and cell migration were obtained by nonlinear 
regression analysis (log (inhibitor) vs. response (three parameters) and fit by the least sum of 
squares. For the saturation binding analyses, Bmax values comparing wildtype MCF-7 cells to 
tamoxifen-resistant (TamR) MCF-7 cells using unpaired Student’s t-test. For all biphasic curves, 
two sites – Fit Ki Nonlinear Regression model in GraphPad Prism has been used. Total cell number 
obtained via the MTT analysis comparing wildtype vs. TamR MCF-7 cells was analyzed by two-
way ANOVA followed by Bonferroni’s post hoc test. For other statistical comparisons, one-way 
ANOVA followed by Newman-Keuls multiple comparisons test was performed. Mean differences 
between treatment groups were considered significant at p<0.05.  
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Chapter 4: Results 
4.1. Effects of C2, C4, C5, C9, and C15 conjugates on MCF-7 (ER+/PR+) cells 
Viability: Cells were exposed to varying concentrations of C2, C4, C5, C9, and C15 and 
their effect on cell viability was assessed. As controls, MCF-7 cells were exposed to vehicle, 
melatonin, tamoxifen, 4-OH-tamoxifen, and combinations of melatonin plus tamoxifen or 4-OH-
tamoxifen. With respect to viability, C4 trended towards being the most potent (IC50=4 nM) vs. 
C2 (IC50=69 mM), C5 (IC50=440 mM), C9 (IC50=107 mM) and C15 (IC50= 34 µM) (Figure 6A; 
Table 4). Tamoxifen is a prodrug that gets converted into 4-OH-tamoxifen by CYP2D6 (Goetz et 
al., 2008). This metabolite of tamoxifen, 4-OH-tamoxifen, has 30 to 100 fold higher binding 
affinity to ERs compared to tamoxifen (Goetz et al., 2008). Because it is expected that melatonin-
tamoxifen conjugates will be converted into melatonin-4-OH-tamoxifen conjugates in vivo, 4-OH-
tamoxifen and melatonin+4-OH-tamoxifen were also run as controls. With respect to efficacy, 
although all five drug conjugates inhibited MCF-7 cell viability compared to vehicle, C4 and C5 
were most efficacious at inhibiting viability by 70-90% compared to vehicle (Figure 6B; Table 5). 
To determine if the drug conjugates displayed equal or superior potency and/or efficacy against 
the controls with respect to effects on MCF-7 cell viability, each drug conjugate was compared 
against melatonin alone, tamoxifen alone, 4-OH-tamoxifen alone, melatonin plus tamoxifen 
(unlinked), and melatonin plus 4-OH-tamoxifen (unlinked) by one-way ANOVA. The potency of 
C2, C4, C5, and C15 were similar to all of the controls except for C9, which was least potent 
(Figure 6C; Table 6). Regarding efficacy, C5 displayed the greatest efficacy (~90% compared to 
vehicle), which was not significantly different from the other controls except for melatonin, which 
only inhibited viability by ~10% compared to the vehicle (Figure 6D; Table 7). 
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Migration: With respect to migration and when compared to each other, C5 (IC50=4 µM), 
and C15 (IC50=1 µM) trended towards being most potent to inhibit MCF-7 cell migration while 
the C2 (IC50=100 µM), C4 (IC50=9 mM), and C9 (IC50=218 mM) were least potent (Figure 7A; 
Table 4). Regarding efficacy, all drug conjugates, except for C15 (-13% of baseline), inhibited 
MCF-7 cell migration equally (+2% to +20% of baseline) compared to the vehicle (Figure 7B; 
Table 5). All drug conjugates, except for C9, were more potent than melatonin plus 4-OH-
tamoxifen to inhibit MCF-7 cell migration but similar to melatonin, tamoxifen, 4-OH-tamoxifen, 
and melatonin plus tamoxifen controls (Figure 7C; Table 6). Regarding efficacy, C2, C4, C5, and 
C9 displayed similar efficacies to inhibit MCF-7 cell migration compared to all controls (+0% to 
+39% of baseline). Both melatonin (-14% of baseline) and C15 were without effect on MCF-7 cell 
migration (Figure 7D; Table 7). 
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Figure 6: Comparison of potency and efficacy between C2, C4, C5, C9, and C15 conjugates 
to inhibit BC cell viability. The potency (IC50) (A) or efficacy (B) of C2, C4, C5, C9, and C15 
on cell viability in MCF-7, MMCs, MDA-MB-231, and BT-549. Similarly, C and D represent the 
potency (IC50) (C) or efficacy (D) of melatonin, tamoxifen, 4-OH-tamoxifen, and unlinked 
melatonin+tamoxifen and unlinked melatonin+4-OH-tamoxifen on cell viability in MCF-7, 
MMCs, MDA-MB-231, and BT-549. Each bar represents the mean ± SD of 3 independent 
experiments for each compound and n=9 for the vehicle since it was run with each experiment 
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conducted. Data were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc t-test 
where significance was defined as p<0.05. 
 
4.2. Effects of C2, C4, C5, C9, and C15 conjugates on MMC (HER2+) cells 
Viability: Cells were exposed to varying concentrations of C2, C4, C5, C9, and C15 and 
their effect on cell viability was assessed. C4 trended towards being most potent (IC50=243 nM) 
followed by C2 (IC50=13 µM), C5 (IC50=6 µM), C9 (IC50=6 µM), and then C15, which was least 
potent (IC50=333 mM) (Figure 6A; Table 4). Concerning efficacy, C2, C4, C5, and C9 inhibited 
MMC cell viability to a similar extent (~20-50% inhibition compared to vehicle). C15 produced a 
minimal non-significant effect (3% inhibition compared to vehicle) (Figure 6B; Table 5). All 
conjugates, except C2, had similar potency to the controls except for C4, which was more potent 
than melatonin plus 4-OH-tamoxifen (Figure 6C; Table 6). Regarding efficacy, all drug 
conjugates, except for C15, inhibited MMC cell viability to a similar extent, which was similar 
(~40% inhibition compared to vehicle) to controls (tamoxifen ± melatonin; 4-OH-tamoxifen ± 
melatonin) except for melatonin (9% inhibition compared to vehicle), which did not inhibit MMC 
viability (Figure 6D; Table 7). 
Migration: The potencies of C4, C5, C9, and C15 to inhibit MMC cell migration, though 
variable, were not significantly different from one another; however, they were significantly more 
potent than that of C2, which had a potency of (IC50=221 mM; Figure 7A; Table 4). Regarding 
efficacy to inhibit MMC cell migration, all drug conjugates, except for C15 (-32% of baseline), 
inhibited MMC cell migration equally (+1% to +44% of baseline) compared to vehicle (Figure 
7B; Table 5). C2 and C9 were the least potent of all drug conjugates when compared to the controls 
(melatonin alone; tamoxifen alone; 4-OH-tamoxifen alone; melatonin + tamoxifen unlinked; 
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Figure 7C; Table 6). C4, C5, and C15 were similar to all controls except C5, which was more 
potent than melatonin plus 4-OH-tamoxifen to inhibit MMC cell migration (Figure 7C; Table 6). 
Regarding efficacy, C2 and C9 displayed the greatest efficacy (~+40% of baseline) to inhibit MMC 
cell migration when compared to all controls. C4 and C5 were similar to all controls (between 
+1% to 7% of baseline) except melatonin, which was without effect vs. vehicle. The C15 was 





Table 4: Comparison of potencies between C2, C4, C5, C9, and C15 conjugates to inhibit BC 
cell viability and migration. Each value represents the average ± SD of potency (IC50) values 
generated from 3-9 individual curves fit by non-linear regression analysis. Data were analyzed by 
one-way ANOVA followed by Newman-Keuls post-hoc t-test where significance was defined as 
p<0.05. Letters denote significance between groups where a = p<0.05 vs. C2; b = p<0.05 vs. C4; 
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Figure 7: Comparison of potency and efficacy between C2, C4, C5, C9, and C15 conjugates 
to inhibit BC cell migration. The potency (IC50) (A) and efficacy (B) of C2, C4, C5, C9, and C15 
on cell migration in MCF-7, MMCs, MDA-MB-231, and BT-549. Similarly, C and D represent 
the potency (IC50) (C) or efficacy (D) of melatonin, tamoxifen, 4-OH-tamoxifen, unlinked 
melatonin+tamoxifen, and unlinked melatonin+4-OH-tamoxifen on cell migration in MCF-7, 
MMC, MDA-MB-231, and BT-549. Each bar represents the mean ± SD of 3 independent 
experiments for each compound and n=9 for the vehicle since it was run with each experiment 
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conducted. Data were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc t-test 
where significance was defined as p<0.05. 
 
4.3. Effect of C2, C4, C5, C9, and C15 conjugates on MDA-MB-231 (ER-/PR-
/HER-) cells 
Viability: Cells were exposed to varying concentrations of C2, C4, C5, C9, and C15 and 
their effect on cell viability was assessed. C9 was the least potent (IC50=145 mM) while the C15 
was most potent (IC50=477 pM) vs C2 (IC50=246 µM), C4 (IC50=37 nM), and C5 (IC50=12 µM) 
(Figure 6A; Table 4). Regarding efficacy, C2, C5, and C9 inhibited cell viability to a similar extent 
(25-37% inhibition compared to vehicle) while the C4 and C15 were without effect and similar to 
the vehicle (Figure 6B; Table 5). The potencies, although variable, were not significantly different 
from one another except for C5, which was more potent than combination melatonin plus 
tamoxifen (Figure 6C; Table 6). Regarding efficacy, C2, C5, and C9 displayed significant 
inhibition (25-37%) when compared to the vehicle while C4 and C15 were without effect; C2 and 
C9 were also significantly different than melatonin alone; and C2, C5, and C9 were also more 
efficacious at inhibiting MDA-MB-231 cell viability vs. 4-OH-tamoxifen alone (Figure 6D; Table 
7). 
Migration: Melatonin-tamoxifen drug conjugate potency and efficacy to inhibit MDA-
MB-231 cell migration revealed no significant differences in potency between C4, C5, and C9; 
however, they were significantly higher compared to C2 and C15, which displayed mM potency 
(Figure 7A; Table 4). Regarding efficacy, all drug conjugates, except for C15, inhibited MDA-
MB-231 cell migration equally (+10% to +35% of baseline) compared to the vehicle; C15 
worsened migration of the cells (Figure 7B; Table 5). When compared to the controls [i.e., 
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melatonin alone, tamoxifen alone, 4-OH-tamoxifen alone, melatonin plus tamoxifen (unlinked), 
and melatonin plus 4-OH-tamoxifen (unlinked)], C2 was the least potent of all drug conjugates to 
inhibit MDA-MB-231 cell migration (IC50=559 mM). C4, C5, C9, and C15 were similar to all 
controls with C5 displaying greater potency (IC50=3 µM) than combination melatonin plus 
tamoxifen (IC50=229 mM; Figure 7C; Table 6). Regarding efficacy, all drug conjugates inhibited 
MDA-MB-231 cell migration compared to vehicle and melatonin; however, C9 had the highest 
efficacy (+35% of baseline) and inhibited cell migration greater than melatonin plus tamoxifen 
(+0% of baseline) and melatonin plus 4-OH-tamoxifen (+2% of baseline). C15 was least 
efficacious (-43% of baseline) while melatonin was without effect (Figure 7D; Table 7). 
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Table 5: Comparison of efficacies between C2, C4, C5, C9, and C15 conjugates to inhibit BC 
cell viability and migration. Each value represents the average ± SD of the maximum inhibitory 
effect of each drug conjugate represented as % of the vehicle for viability and % of baseline for 
migration assays. Values were derived from 3-9 individual curves fit by non-linear regression 
analysis. Data were analyzed by one-way ANOVA followed by Newman-Keuls post-hoc t-test 
where significance was defined as p<0.05. Letters denote significance between groups where a = 
p<0.05 vs. vehicle; b = p<0.05 vs. C2; c = p<0.05 vs. C4; d = p<0.05 vs. C5; e = p<0.05 vs. C9. 
























































































4.4. Effects of C2, C4, C5, C9, and C15 conjugates on BT-549 cells 
Viability: Another triple-negative BC line, BT-549, was screened to assess the potency 
and efficacy of the drug conjugates on viability and migration. With respect to viability, all drug 
conjugates had similar potency to inhibit BT-549 cell viability with potency in the low µM range 
(IC50=2-34 µM; Figure 6A; Table 4). Concerning efficacy, only C4 and C5 inhibited BT-549 cell 
viability (~35% inhibition compared to vehicle); C2, C9, and C15 were without effect and similar 
to the vehicle (Figure 6B; Table 5). All drug conjugates had a similar potency to the controls 
(melatonin, 4-OH-tamoxifen, melatonin plus tamoxifen, and melatonin plus 4-OH-tamoxifen) 
except for tamoxifen, which was least potent (IC50=781 mM; Figure 6C; Table 6). Regarding 
efficacy, C2, C4, and C5 inhibited BT-549 cell viability (~20-35% inhibition compared to vehicle) 
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and melatonin with C15 being least efficacious (~10% inhibition compared to vehicle) (Figure 6D; 
Table 7). 
Migration: Exposure of BT-549 cells to C2, C4, C5, C9, and C15 did not result in 
significant differences in potencies between drug conjugates to inhibit their migration (Figure 7A; 
Table 4). With respect to migration, all drug conjugates had similar potency. Regarding efficacy, 
C2, C4, C5, and C9 inhibited BT-549 cell migration (+0% to +56% of baseline) when compared 
to the vehicle. C15 increased BT-549 cell migration (-61% of baseline) vs. vehicle (Figure 7B; 
Table 5). With respect to control potencies, which ranged between 3-116 µM, no significant 
differences in potencies occurred for any of the drug conjugates except for C2, which had low 
potency (IC50=579 mM; Figure 7C; Table 6). Regarding efficacy, C9 inhibited BT-549 cell 
migration when compared to the vehicle; C2 and C9 also inhibited cell migration to a greater extent 
than melatonin, tamoxifen, or 4-OH-tamoxifen—all of which were without effect on BT-549 cell 
migration. Furthermore, C9 was more efficacious compared to combination melatonin plus 
tamoxifen (+15% of baseline) and combination melatonin plus 4-OH-tamoxifen (+32% of 
baseline). C15 made the BT-549 cells more aggressive (-61% of baseline) when compared to all 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5. Binding affinities of C2, C4, C5, C9, and C15 conjugates to ERs and 
MT1Rs 
Competition binding analysis was performed to identify potential mechanisms of action 
for the anti-cancer actions of the drug conjugates. Specifically, competition of tamoxifen, 4-OH-
tamoxifen and each of the drug conjugates (C2, C4, C5, C9, and C15) for [3H]-estradiol or [125I]-
estradiol binding to ERs or competition of melatonin and each of the drug conjugates for 2-[125I]-
iodomelatonin binding to MT1 melatonin receptor binding assays were conducted. ER binding 
affinity assays were conducted in both mouse uterus ((P.A. Witt-Enderby et al., 2014); US Patent 
8,785,501) and MCF-7 cell lines (Figure 8). Tamoxifen and 4-OH-tamoxifen were used as controls 
for mouse uterus and MCF-7 cells, respectively. As previously published ((P.A. Witt-Enderby et 
al., 2014); US Patent 8,785,501), the affinity of tamoxifen (Kihigh=3 pM and Kilow=6 nM) for ERs 
expressed in mouse uterus displayed a biphasic curve (Figure 8A). In MCF-7 cells, the affinity of 
4-OH-tamoxifen for ERs displayed a monophasic curve with an affinity Ki=46 nM (Figure 8C). 
For C2, C9 and C15, no concentration-dependent inhibition of [3H]-estradiol binding occurred 
(Figures 8E, 8F, 8G) whereas C4 had a binding affinity (Ki=41 nM) similar to 4-OH-tamoxifen 
(Ki=46 nM) between concentrations of 1 pM-10 µM (Figure 8D). As already reported, C5 showed 
a similar binding affinity (Ki=2 nM) as tamoxifen ((P.A. Witt-Enderby et al., 2014); US Patent 
8,785,501) between concentrations 1 pM-1 µM (Figure 8B). Interestingly, all drug conjugates 





4.6. Binding affinities of C4, C5, and G1 to ERs 
Total binding assays were conducted on MCF-7 cells using [3H]-estradiol to elucidate the 
role of C4 and C5 on the membrane-bound G-protein coupled estrogen receptor (GPR30). As 
shown in Figure 8H, all treatments, except for G1, decreased [3H]-estradiol binding compared to 
vehicle whereas G1 increased [3H]-estradiol binding. Combination of C5 with G1 demonstrated 







Figure 8: Competition of C2, C4, C5, C9, or C15 
for [3H]-or [125I]-estradiol binding to ERs 
expressed in mouse uterus or MCF-7 cells. 
Binding of [3H]-or [125I]-estradiol to ERs expressed 
in mouse uterus (A and B) and MCF-7 cells by 
competition binding using tamoxifen (A), 4-OH-
tamoxifen (C) or conjugates C2, C4, C5, C9 or C15) (C-G) and G1 effects on total [3H]-estradiol 
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binding to ERs expressed in MCF-7 cells (H). Data represent the mean ± SD of 3 independent 
experiments performed in duplicate. Figures A and B were taken from (P.A. Witt-Enderby et al., 
2014), US Patent 8,785,501. Data in Figure H were analyzed by one-way ANOVA followed by 
Newman-Keuls post hoc t-test where significance a = p<0.05 vs vehicle; b = p<0.05 vs tamoxifen 
and c = p<0.05 vs G1; d = p< 0.05 vs C4; e = p<0.05 vs C5. 
 
For human MT1 receptors (MT1Rs), all drug conjugates demonstrated concentration-
dependent inhibition of 2-[125I]-melatonin binding with binding affinity (Ki: C2=35 nM; C4=12 
µM; C5= Kihigh=6 pM and Kilow=9 nM; C9=111 nM; C15=56 nM) similar to that of melatonin (Ki 
= 2 nM) (Figure 9). Unlike the increases in ER binding sites observed for all drug conjugates at 
concentrations greater than 10 µM, no drug conjugates except for C5, produced an increase in 2-
[125I]-melatonin binding sites (~90% of control) at 100 µM (Figure 9D). 
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Figure 9: Competition of C2, C4, C5, C9, or C15 for 2-[125I]-iodomelatonin binding to 
MT1Rs expressed in CHO cells. Competition of 2-[125I]-iodomelatonin for binding to MT1Rs 
expressed in CHO cells in the presence of melatonin (A and B) or conjugates C2, C4, C5, C9 or 
C15) (Figures C-G). Data represent the mean ± SD of 3 independent experiments performed in 





4.7. Effects of C4 and C5 conjugates on TamR MCF-7 cells 
Characterization of TamR cells revealed that the binding affinity and density of [3H]-
estradiol did not change in TamR MCF-7 cells (KD=1.1 nM, Bmax=21.4 pmol/mg protein) versus 
WT MCF-7 cells (KD=2.2 nM, Bmax=4.8 pmol/mg protein) even though ER expression was 
decreased in TamR cells vs. WT cells (Figures 10A, 10B and 10C). Further characterization of 
TamR MCF-7 by Schild plot analysis (Chapter 9: Appendix) revealed that the TamR MCF-7 cells 
displayed tight ER/ERE complexation. Analysis of growth patterns of TamR cells revealed that 
over 7 days, TamR cells grew at a faster rate and to a greater extent than WT MCF-7 cells in the 
presence of 4-OH-tamoxifen (Figure 10C) and this was accompanied by a mesenchymal 
phenotype (Figures 10D and 10E) perhaps due to an increase in pERK5 and a decrease in pERK1/2 
(Figures 10A and 10B). These TamR MCF-7 cells are consistent with literature demonstrating low 
ERα, high ERK5, and low ERK1/2 vs wildtype (Barbara A. Drew et al., 2012c; Mendes-Pereira 
et al., 2012; Julie A. Vendrell et al., 2008a; Zhu et al., 2018). 
C4 and C5 were then further tested for their anti-cancer actions in TamR MCF-7 cells. 
Regarding viability, both C4 (IC50=4.27 µM; max inhibition = 83% of vehicle) and C5 (IC50=6.03 
µM; max inhibition = 81% of vehicle) displayed similar potency and efficacy to inhibit TamR cell 
viability (Figure 12A) while the controls were without effect except for tamoxifen which 
demonstrated 27% inhibition of TamR cell viability compared to vehicle (Figure 12A). Regarding 
migration (Figure 12B), both C4 (IC50=4.53 µM; max inhibition = 126%) and C5 (IC50=5.07 µM; 
max inhibition = 137%) exhibited similar potency and efficacy to inhibit TamR cell migration 
similar to melatonin (IC50=1.85 µM; max inhibition = 15%), tamoxifen (IC50=153.4 mM; max 
inhibition = 129%), or melatonin plus tamoxifen (IC50=12.19 mM; max inhibition = 161%); 4-
OH-tamoxifen was least potent and efficacious (IC50=19.11 µM; max inhibition = 50%). 
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Maximum inhibition greater than 100% indicates that the cells were detached from the plate or the 
border width after 24 hr was wider than the 0 hr border width (Figure 12B). 
 
Figure 10: Saturation of [3H]-estradiol binding to ERs expressed in WT (A) and TamR (B) 
MCF-7 cells. Cell counting of WT and TamR MCF-7 cell lines treated with 100 nM of 4-OH-
tamoxifen (C). Each bar represents the total cell number (in ten thousand) expressed as mean ± 
SD. ** P<0.001 day 7th WT MCF-7 cell number vs. day 1st WT MCF-7 cell number by one-way 
ANOVA. *** P<0.001 day 3rd and day 7th TamR MCF-7 cell number vs. day 1st TamR MCF-7 
cell number by one-way ANOVA. ## P<0.01 day 3rd TamR MCF-7 cell number vs. day 3rd WT 
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MCF-7 cell number by 2-way ANOVA with Bonferroni post hoc analysis. ### P<0.01 day 7th 
TamR MCF-7 cell number vs. day 7th WT MCF-7 cell number by two-way ANOVA with 
Bonferroni post hoc test. Immunocytochemistry images of WT MCF-7 (D) and TamR MCF-7 (E) 
cells. 
Figure 11: Basal levels of pERK5 (A), pERK1/2 (B), ERα (C), NF-κB (D), and pAKT (E) in 
TamR MCF-7 and MCF-7 cells. Bands were quantified using Image Studio™ Lite Software (LI-
COR Biosciences, Lincoln, NE) and normalized against β-actin. Each bar represents the mean ± 
SD of 3 independent experiments. Data were analyzed by a two-tailed t-test where a=p<0.05 vs. 
TamR MCF-7. Representative blot images were included in each figure. The upper band indicates 
the protein of interest and the lower band indicates the β-actin band. 
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Figure 12: Effect of C4, C5, melatonin, tamoxifen, 4-OH-tamoxifen, and unlinked 
melatonin+tamoxifen on TamR MCF-7 cell viability and cell migration. Data in (A) 
demonstrate the effect of C4, C5, melatonin, tamoxifen, 4-OH-tamoxifen, or unlinked 
melatonin+tamoxifen on TamR MCF-7 cell viability and cell migration (B). Data represent the 
mean ± SD of 3 independent experiments performed in duplicate. 
 
4.8. Effects of C4 and C5 conjugates on TU-BcX-4IC cells and TU-BcX-4QAN 
tumor tissue 
C4 and C5 were then tested for their anti-cancer actions in TU-BCx-4IC cells. Regarding 
viability, both C4 (IC50=181.5 mM; max inhibition=78% of vehicle) and C5 (IC50=304.2 mM; max 
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inhibition =65% of vehicle) displayed similar potency and efficacy to inhibit cell viability while 
melatonin was without effect; and melatonin plus tamoxifen demonstrated 80% inhibition of cell 
viability compared to the vehicle (Figure 13A). Regarding migration (Figure 13B), both C4 
(IC50=211.1 µM; max inhibition = 145%) and C5 (IC50=80.38 µM; max inhibition =145%) 
exhibited similar and greater potency and efficacy compared to melatonin (IC50=168.6 mM; max 
inhibition=21%), tamoxifen (IC50=514.9 mM; max inhibition=159%), or melatonin plus 
tamoxifen (IC50=116.8 mM; max inhibition=155%). Maximum inhibition greater than 100% 
indicates that the cells were detached from the plate or the border width after 24 hr was wider than 
the 0 hr border width. In TU-BcX-4IC cells, western blot analysis data demonstrated that C4 and 
C5 decreased pERK1/2 levels, and C5 increased NF-ᴋB with trends towards an increase occurring 
with C4 (Figure 13C) similar to what occurred in the other triple-negative cells, MDA-MB-231 
and BT-549 (Table 8). However, C4 and C5 had no significant effects on pERK5 levels in TU-
BcX-4IC cells (Figure 13C). Both conjugates did not change pERK1/2, pERK5, and NF-ᴋB levels 
in PDX tumor tissue, although C4 and C5 trended towards a reduction in pERK5 levels (Figure 
13C). Further characterization of the TU-BCx-4IC cells for melatonin binding sites or estrogen 
binding sites revealed total specific binding of 2-[125I]-iodomelatonin (7.6 ± 3.9 fmol/mg protein) 







































































































































































































Figure 13: Effect of C4, C5, melatonin, tamoxifen, 4-OH-tamoxifen, and unlinked 
melatonin+tamoxifen on TU-BCx-4IC cell viability and cell migration and TU-BcX-4QAN 
tumor tissue. Data demonstrate the effect of C4, C5, melatonin, tamoxifen, or unlinked 
melatonin+tamoxifen on TU-BCx-4IC cell viability (A) and cell migration (B). Expression of 
pERK1/2, pERK5, and NF-ᴋB were analyzed in TU-BcX-4QAN tumor tissue and TU-BCx-4IC 
cells (C), and total specific binding of 2-[125I]-iodomelatonin or [3H]-estradiol was measured in 
TU-BCx-4IC cells (D). Data represent the mean ± SD of 3 independent experiments performed in 
duplicate. Significance was defined as p<0.05. In A, B, (*) indicates significance from all 
treatments except 100µM treatments for all groups. In (C), “a” indicates significance compared to 
vehicle and “b” indicates significance compared to 10µM melatonin. Images of cells in (A) and 
(B) were exposed to vehicle or 100µM of treatment listed within each series of graphs. 
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4.9. Role of MEK1/2, MEK5 and PI3 kinases in mediating C4 and C5 effects 
on BC cell viability and migration 
MCF-7: MEK1/2, MEK5, and PI3K were chosen due to their role in BC cell viability and 
migration. For example, inhibition of MAPK by MEK inhibitors demonstrated anti-invasive 
properties in breast carcinoma cell lines (Katagiri et al., 2010). PD98059-mediated inhibition of 
MEK1/2 decreased proliferation and promoted migration in MCF-7 and MDA-MB-231 cells via 
dose- and time-dependent manner (Y. Zhao et al., 2017). The pro-survival protein, MEK5, was 
found to be overexpressed in drug-resistant MCF-7 cells; and MEK5 was responsible for 
chemoresistance and inhibition of apoptosis (Weldon et al., 2002). Furthermore, ERK5 was found 
to be overexpressed in 25% of BC patients and in 84 tumor tissues examined, ERK5 was inversely 
correlated with disease-free survival (Barbara A. Drew et al., 2012b). Several studies have shown 
that PIK3CA mutation, an activating mutation, was found in 18-40% of BC patients (Isakoff et al., 
2005). This mutation was found to be a good predictor of the overall survival of HER2+ BC 
patients (Vasan et al., 2019). Furthermore, the FDA approved alpelisib, a PI3K inhibitor in 
combination with fulvestrant to treat advanced or metastatic breast cancer patients containing the 
PIK3CA gene mutation ("First PI3K Inhibitor for Breast Cancer," 2019; Verret et al., 2019). 
All inhibitors (PD98059, Bix02189, and pictilisib) attenuated MCF-7 (ER+) cell viability 
on their own and when combined with C4 or C5, only pictilisib (PI3 kinase inhibitor) enhanced 
C4- and C5-mediated MCF-7 cell viability while PD98059 and Bix02189 produced subtle (if any) 
inhibitory effects (Figures 14A-14D, 18A). Regarding migration and when added alone, PD98059 
and Bix02189 were without effect and pictilisib inhibited MCF-7 cell migration vs. vehicle. When 
combined with C4, all inhibitors (PD98059, Bix02189, pictilisib) enhanced C4-mediated 
inhibition of MCF-7 cell migration (Figures 14E, 14G) (See Figure 18B for schematic). For C5, 
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co-administration with PD98059 was without effect; co-administration with pictilisib enhanced 
the inhibitory effect of C5; and co-administration with Bix02189 blocked C5’s effects (Figures 
14F, 14H; 18C). 
 
Figure 14: Effect of MEK1/2, MEK5, or PI3K inhibitors on cell viability and migration of 
C4 or C5 in MCF-7 cells. Cell viability (A-D) and migration (E-H) of C4 or C5 in the absence or 
presence of PD98059, Bix02189, or pictilisib in MCF-7 cells Each point represents the mean ± SD 
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of 3 independent experiments. Data were analyzed by one-way ANOVA followed by Newman-
Keuls post-hoc t-test where significance was defined as p<0.05. 
 MMC: Bix02189 and PD98059 alone were without effect while pictilisib alone inhibited 
MMC viability (Figure 15). Combination of Bix02189 (Figure 15A) or pictilisib (Figure 15C) with 
C4 enhanced MMC viability. PD98059 added in combination with C4, blocked C4-mediated 
MMC viability at C4 concentrations (1 pM-1 µM). C5 inhibited MMC viability, which was 
enhanced in the presence of Bix02189 (Figure 15B) or pictilisib (Figure 15D), but not PD98059 
(Figure 15B). Regarding MMC migration, PD98059, Bix02189 (Figure 15E), or pictilisib (Figure 
15G) each alone inhibited MMC migration; however, when combined with C4 only PD98059 and 
pictilisib enhanced C4’s inhibitory actions (Figure 18F). For C5, PD98059 and Bix02189 
enhanced C5’s inhibitory actions on MMC migration at C5 concentrations ranging from 1 pM-1 
µM where then no further enhancement occurred at higher (>1 µM) concentration of C5 (Figure 
15F). Pictilisib enhanced C5-mediated MMC migration at all concentrations tested except the 
highest concentration of 100 µM (Figures 15H; 18G). 
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Figure 15: Effect of MEK1/2, MEK5, or PI3K inhibitors on cell viability and migration of 
C4 or C5 in MMC cells. Cell viability (A-D) and migration (E-H) of C4 or C5 in the absence or 
presence of PD98059, Bix02189, or pictilisib in MMC cells. Each point represents the mean ± SD 
of 3 independent experiments. Data were analyzed by one-way ANOVA followed by Newman-
Keuls post-hoc t-test where significance was defined as p<0.05. 
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MDA-MB-231: No effect of the inhibitors occurred either alone or in combination with 
C4 and C5 except for pictilisib, which inhibited MDA-MB-231 cell viability when added alone 
and when compared to vehicle (Figure 16). Only at one concentration (1 nM C5) did pictilisib 
block its effect (Figures 16C and 16D; 18H and 18I). Regarding migration, PD98059 and 
Bix02189 alone were without effect while pictilisib inhibited cell migration vs. vehicle. When 
combined with C4, all inhibitors enhanced C4-mediated inhibition of cell migration (Figures 16E 
and 16G). For C5, pictilisib, added in combination with C5, enhanced cell migration while 
PD98059 and Bix02189 blocked C5’s inhibitory effects (Figures 16F and 16H). 
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Figure 16: Effect of MEK1/2, MEK5, or PI3K inhibitors on cell viability and migration of 
C4 or C5 in MDA-MB-231 cells. Cell viability (A-D) and migration (E-H) of C4 or C5 in the 
absence or presence of PD98059, Bix02189, or pictilisib in MDA-MB-231 cells. Each point 
represents the mean ± SD of 3 independent experiments. Data were analyzed by one-way ANOVA 
followed by Newman-Keuls post-hoc t-test where significance was defined as p<0.05. 
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BT-549: PD98059 or Bix02189 alone was without effect on BT-549 cell viability while 
pictilisib alone produced some inhibitory effects. When added in combination with C4, all 
inhibitors slightly, albeit significantly, inhibited C4-mediated inhibition of BT-549 viability at C4 
concentrations higher than 1 µM and for C5, the same occurred in the presence of Bix02189 or 
pictilisib but not PD98059 (Figures 17A-17D and 18J). For migration, PD98059 and Bix02189 
alone were without effect while pictilisib inhibited BT-549 cell migration (vs. vehicle). When co-
administered with Bix02189 or pictilisib but not PD98059, C4-mediated effects on BT-549 cell 
migration was enhanced (Figures 17E-17H and 18K). Pictilisib, added in combination with C4 or 
C5, enhanced their inhibitory effects on BT-549 cell migration while PD98059 was without effect 
(Figures 17G and 17H). The same findings occurred for C5 except that Bix02189 blocked—not 
enhanced—the inhibitory effect of C5 on BT-549 cell migration (Figures 17E and 17F). 
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Figure 17: Effect of MEK1/2, MEK5, or PI3K inhibitors on cell viability and migration of 
C4 or C5 in BT-549 cells. Cell viability (A-D) and migration (E-H) of C4 or C5 in the absence or 
presence of PD98059, Bix02189, or pictilisib in BT-549 cells. Each point represents the mean ± 
SD of 3 independent experiments. Data were analyzed by one-way ANOVA followed by 
Newman-Keuls post-hoc t-test where significance was defined as p<0.05. 
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4.10. Effect of C4 and C5 melatonin-tamoxifen drug conjugates on pERK5, 
pERK1/2, pAKT, NF-κB, RUNX2, and β1-INTEGRIN protein levels 
To identify the signaling proteins/cascades involved in C4- or C5-mediated inhibition of 
breast cancer, western blot analysis was performed in each cell line under basal (unstimulated) 
conditions; or following 15 min exposure to each conjugate (C4 or C5) alone or in combination 
with PD98059 (MEK1/2 inhibitor), Bix02189 (MEK5 inhibitor) or pictilisib (PI3 kinase inhibitor). 
Treatment effects on pERK1/2, pERK5, pAKT, RUNX2, NF-ĸB, and β1-INTEGRIN were 
analyzed. Due to the enormity and complexity of the analyses, all data are presented in Tables 9-
15 and schematics are shown in Figure 18 (indicated in blue) for clarity, whereas significant 



































































































































































































































































































































































































































































































































































In general, the major findings of the western blot analyses for MCF-7 cells demonstrate 
that all three pathways (MEK1/2, MEK5, PI3 kinase), when inhibited by PD98059, Bix02189, or 
pictilisib, respectively, enhance the inhibitory effects of C4 on MCF-7 viability and migration and 
cross-talk (mainly inhibitory actions) between MEK/pERK1/2 and MEK5/pERK5 occurs. This 
cross-talk between MAPK members has been demonstrated in other reports too (B. A. Drew et al., 
2012a; Lochhead et al., 2016). For C5, although both MEK1/2 and PI3 kinase pathways lay parallel 
to and enhance the inhibitory effects of C5 when inhibited by PD98059 and pictilisib, respectively, 
it was MEK5 that was critical in mediating C5’s actions on MCF-7 viability and migration. 
RUNX2 expression was inhibited in the presence of C4 and C4 plus pictilisib. β1-INTEGRIN 
expression levels were not significantly changed in the presence of C4 or C5 (Tables 9-12; Figures 
19A-19C). 
For MMC (HER2+) breast cancer cells, the western blot analysis revealed that the 
MEK1/2/pERK1/2 pathway appeared to play a more central role possibly through co-modulation 
of NF-ĸB, pERK5, and β1-INTEGRIN. Western blot analyses revealed that C5 activated (1 nM) 
or inhibited (10 µM) NF-ĸB or β1-INTEGRIN levels that were concentration-dependent (see blue 
dotted lines; Figures 18E, 18G). For C5, the inhibitor analysis revealed that crosstalk between 
MEK1/2/pERK1/2 and MEK5/pERK5 occurred and that inhibition of pERK5 may be through a 
MEK1/2/pERK1/2-mediated inhibition of MEK5 (Figure 18G). No effect of C4 or C5 on RUNX2 
expression was observed (Tables 9-12). 
For the triple-negative breast cancer line, MDA-MB-231 cells, relationships between PI3 
kinase/pERK1/2 and MEK5/pERK5 on NF-ĸB expression were observed where pictilisib 
inhibited pERK1/2 levels and Bix02189 increased NF-ĸB expression (Figure 18H). C5 increased 
NF-ĸB and β1-INTEGRIN levels, whereas MEK1/2-mediated crosstalk with MEK5/pERK5 
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occurred and PI3 kinase-mediated modulation of NF-ĸB, RUNX2, and β1-integrin was observed 
(Figure 18I). 
For BT-549 triple-negative breast cancer cells, the MEK5/pERK5 and PI3 kinase signaling 
pathways lay parallel to and facilitated the inhibitory actions of C4 in the presence of Bix02189 
and pictilisib, respectively, possibly by modulating pERK1/2 as revealed through western blot 
analysis (Table 8; Figure 18K); PD98059 alone inhibited BT-549 cell migration and these effects 
may be mediated through NF-ĸB (Figure 18K). For C5, western blot analysis revealed that C5 
modulates NF-ĸB; however how NF-ĸB fits into these signaling cascades remains unclear and 
needs further study (Figure 18L). MEK/1/2 inhibition by PD98059 inhibited BT-549 migration 
and these effects are likely mediated through inhibition of pERK1/2 revealed by western blot 
analysis. No effect of C4 or C5 on β1-integrin or RUNX2 expression occurred in these cells 







Figure 18: Summary of mechanisms of action underlying C4 or C5 in breast cancer cells. 
Depicted is a summary of the mechanisms of action underlying C4 (A, B, D, F, H, J, K) or C5 (C, 
E, G, I, J, L) in MCF-7 (A-C), MMC (D-G), MDA-MB-231 (H, I) or BT-549 (J-L) BC cells. The 
lines connecting the proteins indicated in black were the relationships deduced from the viability 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As shown in Figure 19, basal expression of all proteins was assessed between cell lines and 
significant differences in some of these proteins existed between the triple-negative BC lines, 
MDA-MB-231 and BT-549, and the ER+-expressing BC line, MCF-7. Specifically, pERK1/2 
levels were highest in MDA-MB-231 cells compared to MCF-7 and BT-549 cells; and in BT-549 
cells, levels of NF-ĸB were greatest when compared to MCF-7 cells and β1-INTEGRIN levels 
were highest when compared to MCF-7 or MDA-MB-231 cells (Figure 19). 
 
B  











 MCF-7 MMC MDA-MB-231 BT-549 
β1-integrin 
    
pAKT 
    
β-actin 
    
 
Figure 19: A. Basal levels of pERK5, pERK1/2, NF-ĸB, RUNX2, β1-INTEGRIN, and pAKT in 
MCF-7, MMC, MDA-MB-231, and BT-549 BC cells. Bands were quantified using Image 
Studio™ Lite (LI-COR Biosciences, Lincoln, NE) and normalized against β-actin. Each bar 
represents the mean ± SD of 3 independent experiments. Data were analyzed by one-way ANOVA 
followed by Newman-Keuls post-hoc t-test where a=p<0.05 vs MCF-7; b=p<0.05 vs MMC; 
c=p<0.05 vs MDA-MB-231. B. Representative blot images were included below the figure. 
 
4.11. Assessment of C4 and C5 drug conjugates metabolism both in vitro and 
in vivo 
4.11.1. Microsomal incubation of tamoxifen, C4, and C5 
Tamoxifen was incubated for up to 20 min in the absence of microsomes, and levels 
assessed by HPLC-UV. No change in drug levels occurred suggesting that it was stable over time 
during the incubation period (data not shown). To assess tamoxifen oxidative metabolism by liver 
microsomes, incubations were conducted in the presence of NADPH for either 10 or 20 min in 
mouse or human microsomes, respectively. As shown in Table 13, there was approximately a 40% 
loss in 10 min in mouse microsomes and in 20 min in human microsomes. The observed loss in 
the human experiment is consistent with the preponderance of CYP-mediated metabolism of 
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tamoxifen (Dahmane et al., 2014). The same assay in both species was conducted as described for 
tamoxifen to assess the susceptibility of C4 and C5 conjugates to liver microsomal metabolism. 
Loss of either compound was similar to that observed for tamoxifen in the respective species 
(Table 13). 
4.11.2. Pharmacokinetics of tamoxifen, C4 and C5 in mice 
Tamoxifen was administrated by the SC route; whereas, C4 and C5 were administered 
through SC and PO routes. As summarized in Table 13, exposure to C5 following PO 
administration was substantially lower compared to C4. In contrast, exposure parameters (Cmax 
and AUC0-24) were similar for the two compounds following SC administration, and they were 
similar to those calculated following the same dose of tamoxifen by this route (Table 13). Based 
on the differences between C4 and C5 following oral dosing relative to the similar exposures 
obtained following SC dosing, the oral bioavailability relative to SC administration of C4 was 






































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5: Discussion 
In US Patent 8,785,501, C5 was used to screen for ESR1 and MT1R receptor binding and 
test the uterus growth in mice (P.A. Witt-Enderby et al., 2014). Similar approaches were taken to 
screen different hybrid drug conjugates for anti-breast cancer activity both in-vitro and in-vivo 
(Hasan et al., 2018). In this study, we have synthesized five melatonin-tamoxifen drug conjugates 
linked with different alkane chains. Two conjugates (C2 and C4) have shorter linker length than 
C5, and two conjugates (C9 and C15) have longer linker length than C5. These five drug 
conjugates were screened for cell viability, cell migration, ESR1/MT1R receptor binding for anti-
breast cancer activity.  
Although, statistically, no drug conjugates demonstrated significant potency differences 
when compared between each other (i.e., C2 vs C4 vs C5 vs C9 vs C15), efficacy differences were 
observed for C4 and C5, which demonstrated the greatest efficacy to inhibit cell viability compared 
to the other conjugates in MCF-7 and MMC cells. Because the C4 and C5 conjugates inhibited 
both viability and migration in MCF-7 and MMC cells, the decreases in migration could be due to 
an attenuation in proliferation.  However, for the TNBC cells, MDA-MB-231 and BT-549 cells, 
differences between C4 and C5 on proliferation and migration were observed indicating that the 
conjugates were inhibiting cellular migration beyond that of a reduction in cellular viability and 
using different signaling pathways dependent on the type of TNBC.  For example, C5 inhibited 
cell viability in MDA-MB-231 and both C4 and C5 inhibited cell viability in BT-549 cells. The 
different actions between MDA-MB-231 and BT-549 could be due to the mutations that result in 
their TNBC phenotype—in MDA-MB-231 cells, a constitutively activating KRAS/BRAF 
mutation occurs increasing MAPK signaling pathways in these cells while in BT-549 cells, a 
PTEN mutation occurs preventing PI3K/Akt signaling inactivation in these cells (Torbett et al., 
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2008). The western blot analyses performed on these cells also supports this idea.  For example, 
in MDA-MB-231 cells, C5 modulated MEK1/2 and 5, which lay downstream from the 
KRAS/BRAF pathway and C4 and C5 both modulated MEK1/2/5 and PI3K kinases in BT-549 
cells. Also, BT-549 cells express a higher level of the ER-β2 isoform compared to MCF-7 cells, 
which promotes cell proliferation and invasion (Bialesova et al., 2017).  This may explain why 
BT549 cells have a much greater proliferative and invasive phenotype than MCF-7 cells and why 
differences were observed for C4- and C5-mediated inhibitory actins on viability and migration 
between these cell lines. 
For the control groups, both tamoxifen and 4-OH-tamoxifen exhibited similar effects to 
inhibit cell viability and migration, where tamoxifen or 4-OH-tamoxifen inhibited viability up to 
87% compared to the vehicle in ER+/PR+ (MCF-7) cells and the inhibition was about 45% in 
HER2+ (MMC) and TNBC (MDA-MB-231 and BT-549) cells. This was unexpected since 
tamoxifen is a prodrug, which shows less binding affinity compared to the metabolized form, 4-
OH-tamoxifen. Perhaps, in TNBC cell lines, tamoxifen is working through GPR30, and/or non-
receptor-mediated action targeted to the mitochondria (Figure 21) to continue to promote its anti-
cancer actions as a prodrug (Nazarewicz et al., 2007). The findings that melatonin alone was 
without effect to inhibit cellular migration demonstrates the essentiality of tamoxifen as a 
component of the melatonin-tamoxifen drug conjugates, C4 and C5, to promote their anti-cancer 
actions in TNBC. 
The uniqueness of C4 and C5 may also be due to their binding to their respective receptors, 
especially ERs.  For example, higher concentrations of C4 and C5 increased [3H]-estradiol binding 
to ERs suggesting that the melatonin component of the melatonin-tamoxifen conjugates is 
influencing the number of [3H]-estradiol binding sites, which was not observed with tamoxifen or 
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4-OH-tamoxifen alone.  Perhaps one of the mechanisms underlying the anti-cancer actions of C4 
and C5 is due to an increase in ERs enhancing the efficacy of tamoxifen to inhibit cell proliferation 
and migration. For melatonin receptor binding, C5 but not C4 increased the binding of [125I]-
iodomelatonin to the MT1R.  Because melatonin alone and C4 alone did not increase [125I]-
iodomelatonin to the MT1R suggest that the tamoxifen component of the melatonin-tamoxifen 
drug conjugate of C5 and the linker length may be important determinants as to how C4 and C5 
inhibit BC uniquely from each other. 
Our data demonstrate that C4 and C5 drug conjugates have the greatest potential as novel 
BC drugs compared to the C2, C9, and C15 drug conjugates supported by their efficacy to inhibit 
an array of diverse BC cells and their binding profiles at ERs and MT1Rs. C4 and C5 demonstrated 
low nM or µM potency to inhibit BC cell viability (65-80% inhibition compared to vehicle) making 
them attractive anti-cancer drug candidates in ER+, HER2+, and triple-negative BCs that include 
PDX-TNBC. 
Hence, C4 and C5 were selected for further evaluation in BC cells including TamR and 
PDX-TNBC cells. TamR MCF-7 cells have a mesenchymal morphology, indicating that the cells 
have undergone an epithelial to mesenchymal transition and they also display an accelerated 
growth rate in the presence of 4-OH-tamoxifen compared to the WT MCF-7 cells perhaps due to 
increased pERK5 (prosurvival kinase) activity and lower pERK1/2 (kinase involved in 
differentiation and anti-proliferative when located in the cytoplasm) activity (Eapen et al., 2011; 
Mebratu & Tesfaigzi, 2009; Sethi et al., 2010b). The findings that [3H]-estradiol binding 
characteristics (affinity and Bmax) were not different between TamR and WT MCF-7 cells suggest 
that other ERs (i.e., non-genomic ERs like GPR30) may be playing more of a role in C4- and C5-
mediated anti-cancer actions. However, ER-α expression was found to be lower in TamR MCF-7 
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cells compared to WT MCF-7 cells, whereas, low ER-α is associated with poor prognosis in 
patients with tamoxifen failure (J. A. Vendrell et al., 2008b). This idea is supported by the findings 
that tamoxifen could activate GPR30 in endometrial (Ishikawa) cells (Lin et al. 2009). The 
detection of [3H]-estradiol binding sites in TU-BCx-4IC (PDX-TNBC) cells also supports this 
idea. C4 and C5 inhibited cell viability and migration in TamR MCF-7 cells with high efficacy 
and potency making these compounds potentially useful for treating recurrent or TamR BC. 
Enhanced inhibition of cell viability compared to the controls (melatonin, tamoxifen, 4-
OH-tamoxifen, melatonin+tamoxifen, and melatonin+4-OH-tamoxifen) indicate that conjugation 
between melatonin and tamoxifen is required to be effective in the tamoxifen-resistant BC model. 
Perhaps melatonin, when conjugated, potentiates tamoxifen activity by inhibiting ER-ERE 
binding. Furthermore, migration data suggest that compared to the controls, conjugates can 
demonstrate a greater extent of anti-migratory effect from low concentration to a high 
concentration. The findings were validated using PDX models that represent clinically aggressive 
TNBC tumors, TU-BcX-4IC, and TU-BcX-4QAN. Although melatonin receptors were found in 
the PDX-TNBC cells, melatonin alone did not produce any effect. At 100uM concentration, 
tamoxifen, 4-OH-tamoxifen, melatonin+tamoxifen, C4, and C5 inhibited viability as well as 
detached the cells from the plate. Hence, the data suggest that the conjugates can exhibit anti-
cancer action in patient-derived BC cells possibly by regulating MEK1/2 and NF-кB pathways. 
Future studies should explore downstream effectors like ERK1/2, ERK5, or PI3K pathways. 
The involvement of MEK1/2, MEK5, and PI3 kinases in C4- or C5-mediated anti-cancer 
actions was chosen because of their involvement in MT1R/ESR1-mediated BC signaling (Figure 
20) (Araki & Miyoshi, 2018; Kastrati et al., 2017; Kumar et al., 2018; Martinelli et al., 2017; 
Simoes et al., 2016; Temraz et al., 2015). 
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Figure 20: Molecular targets for melatonin, tamoxifen and the kinase inhibitors against MEK1/2 
(PD98059), MEK5 (Bix02189) and PI3K (pictilisib) in MCF-7 (ER+), MMC (ER-/PR-/HER2+) 
and TNBC (ER-/PR-/HER2-) cell lines HER2, MTR, ER, and GPR30 in BC cells. 
C4 and C5 inhibited MCF-7 cell viability in parallel with MEK1/2, MEK5, and PI3 kinase 
but not through these pathways (Figure 21). For cellular migration, the inhibitory effects were 
shown to be mediated through MEK5 for C5 and not through MEK1/2 while the PI3 kinase 
pathway (when inhibited) worked in parallel with C5 to enhance its inhibitory action. However, 
when MCF-7 cells were treated short-term (15 min) with C5, there was no change in 
MEK5/pERK5, which suggests that chronic treatment of C5 modulates MEK5 through other 
signaling pathways. These data suggest that C4 and C5 work similarly with respect to viability but 
not migration and that the number of carbons linking melatonin with tamoxifen influenced the 
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outcome with respect to MCF-7 cell migration and the signaling cascade to which the drug 
conjugate modulated. 
For MMCs, the findings suggest that lower concentrations of C4 may be working through 
the MEK1/2 pathway to influence MMC viability and that C5-mediated inhibition of MMC 
viability works in concert with but not through PI3 kinase and possibly MEK5 but not MEK1/2 
(Figure 21). For migration, the PI3K and MEK1/2 pathways enhanced C4’s inhibitory action while 
the combination of PD98059, Bix02189 and pictilisib with C5 enhanced its inhibitory actions. 
However, C4 and C5 modulated NF-кB and β1-integrin suggesting that the conjugates may 
regulate other signaling proteins to induce their action. 
For MDA-MB-231 cells, the data suggest that the MEK1/2, MEK5, and PI3K pathways 
(when inhibited) work in concert with C4 to inhibit MDA-MB-231 migration and for viability, 
only the PI3 kinase pathway cooperated with C4 to inhibit MDA-MB-231 (Figure 21). Pictilisib 
enhanced C5-mediated inhibition of viability and migration like C4; however, C5 inhibited MDA-
MB-231 cell migration through MEK1/2 and MEK5. Similar to the NF-кB modulation by C5 in 
PDX-TNBC cells, C4 stimulated NF-кB and C5 stimulated NF-кB and β1-integrin levels. 
Although NF-кB is a pro-proliferative and pro-survival protein, other studies have demonstrated 
that inhibition of NF-кB can promote ras-mediated invasive epidermal cell growth (Xia et al., 
2018). These findings suggest that the C4- and C5-mediated stimulation of NF-кB may be 
attenuating ras-mediated invasive properties of the TNBCs. 
For BT-49 cells, C4-mediated inhibition of viability occurred through MEK1/2, MEK5, 
and PI3 kinase signaling pathways while C5 inhibited viability through MEK5 and PI3 kinase and 
not MEK1/2 (Figure 21). For C4, the MEK5 and PI3 kinase pathways (when inhibited) worked in 
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concert with C4 to enhance its inhibitory actions on BT-549 migration. For C5, Bix02189 blocked 
C5’s inhibitory effects on BT-549 cell migration suggesting the C5-mediated inhibition of BT-549 
cell migration occurs through MEK5; however, the PI3 kinase pathway worked in concert with C5 
to enhance its anti-migratory effects but only when PI3 kinase was inhibited by pictilisib. These 
data demonstrate that unique pharmacophores are being produced in the presence of C4 or C5 that 
explain, in part, their anti-cancer actions and their uterine-protective actions not observed with the 
co-administered but unlinked controls (i.e., melatonin + tamoxifen or melatonin +4-OH-
tamoxifen). 
The data demonstrate enhanced efficacy of C4 and C5 compared to the unlinked controls 
likely due to unique ER/MT1R and/or intracellular protein interactions (Figure 21).  For example, 
in MCF-7 (ER+) BC cells, pERK1/2, pERK5 and NF-ĸB were the proteins significantly modulated 
by C4 or C5. For MMC (HER2+) BC cells, pERK1/2 appeared to play a more central role possibly 
through co-modulation of NF-ĸB, pERK5, and β1-INTEGRIN. For the triple-negative BC line, 
MDA-MB-231, pERK1/2 and pERK5-mediated inhibition of NF-ĸB were modulated by C4 while 
C5 effects on NF-ĸB and β1-INTEGRIN expression levels; or pERK1/2 cross-modulation of 
pERK5 and NF-ĸB; or PI3K-dependent inhibition of NF-ĸB, RUNX2, and β1-INTEGRIN may 
underlie its anti-cancer effects in MDA-MB-231 cells. For BT-549 triple-negative BC cells, C4- 
and C5-mediated effects on NF-ĸB or PI3K-dependent regulation of pERK1/2 may underlie its 




Figure 21: Abridged mechanism of C4 and C5 effects in MCF-7, MMC and TNBC 
cell lines. The red arrow indicates that kinase has been modulated for drug conjugates-mediated 
change in viability in a certain cell line. The green arrow indicates that kinases have been 
modulated for change in migration mediated by drug conjugates in certain cell lines. The dotted 
line indicates kinases worked parallel with the drug conjugates for cell viability and cell migration 
in the specific cell line. The blue box indicates the proteins were changed by the conjugate 
treatments, where the data was obtained from western blot method. 
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These inhibitor studies demonstrate that C4 and C5 are not acting “typically” at ERs and 
MT1Rs and suggest that novel pharmacophores are being created in a cancer cell-specific manner 
to produce their diverse anti-cancer actions. These unique pharmacophores created by C4 and C5 
may be attributed to the type of linker connecting melatonin to tamoxifen (i.e., cleavable or non-
cleavable) to influence the pharmacological characteristics of anti-cancer drugs as shown in Fig. 
22 and as reviewed (Hasan et al., 2018).  
This idea is supported by the findings that (1) C4 and C5 inhibited BC lines devoid of 
estrogen receptors (MMC, MDA-MB-231, BT-549); (2) that C4 and C5 displayed unique binding 
characteristics at ERs and MT1Rs and (3) uterine-protection occurred for C5, which was not 
observed when melatonin and tamoxifen were co-administered but unlinked. Regarding (3), it was 
demonstrated that a 3-day administration of the C5 prevented uterine stimulation compared to 
17-estradiol (E2) alone, tamoxifen alone, and melatonin plus tamoxifen co-administered but 
unlinked in FVB/n OVX mice ((P.A. Witt-Enderby et al., 2014); US Patent 8,785,501). This 
observation suggests that the melatonin component of the C4 or C5 drug conjugates may be 
opposing tamoxifen’s uterine-enhancing actions by inhibiting ER binding to EREs thus decreasing 
ERE-mediated gene transcription in the uterus as shown (Hu et al., 2015; Rato et al., 1999). Even 
though the uterotropic effects of tamoxifen were lessened in the presence of melatonin in an 
unlinked manner, the findings that the melatonin-tamoxifen drug conjugates demonstrated an 
enhance inhibiting action on the uterus suggests that some unique interaction between melatonin 
receptors and estrogen receptors (genomic and non-genomic) is occurring in the uterus (See blue 
and orange boxes in Figure 22). 
Basal expression of pERK1/2, NF-ĸB, and β1-INTEGRIN could also account for the 
differential actions of C4 and C5 on BC cell viability, migration, and modulation of signaling 
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cascades in MCF-7 cells, MMCs, MDA-MB-231, and BT-549 cells. Phospho- ERK1/2 levels were 
highest in MDA-MB-231 cells versus MCF-7 and BT-549 cells; NF-ĸB levels were highest in BT-
549 cells vs. MCF-7 cells; and β1-INTEGRIN levels were highest in BT-549 cells when compared 
to MCF-7 or MDA-MB-231 cells. The preference of C4 and C5 for the MEK1/2 pathway in MDA-
MB-231 cells may be attributed, in part, to its high basal levels of pERK1/2 and the strong PI3 
kinase inhibitory effect in BT-549 cells when combined with C4 or C5 may be attributed to its 
high NF-ĸB and β1-integrin levels. All of these proteins analyzed have been shown to either lay 
downstream of MEK1/2, MEK5, and/or PI3 kinase and play significant roles in BC development, 
growth, and progression (Kumar et al., 2018; Simoes et al., 2016; Kastrati et al. 2017; Temraz et 
al. 2015; Martinelli et al., 2017; Araki and Miyoshi, 2017). Their inhibition by C4 or C5 alone or 
in combination with the MEK1/2, MEK5, or PI3 kinase inhibitors opens a novel and rich area for 
BC drug development. 
Using a mouse and human microsomal system, C4 and C5 followed similar metabolic loss 
as tamoxifen, demonstrating oxidative, presumably cytochrome P450-dependent metabolism. In-
vivo pharmacokinetic analysis in mice demonstrated that both C4 and C5 had exposures similar to 
tamoxifen following subcutaneous administration, suggesting similar pharmacokinetic 
characteristics to tamoxifen. Following oral administration to mice, rats, and humans, tamoxifen 
is extensively metabolized (Fromson et al., 1973; Kisanga et al., 2004). In mice, the oral 
bioavailability of tamoxifen compared to the subcutaneous route was < 10% following doses of 
either 4 or 10 mg/kg doses for each route (Reid et al., 2014). A similar estimate of oral relative to 
subcutaneous bioavailability was observed for the C4 conjugate (Table 6). The lower 
bioavailability of C5 compared to C4 following oral administration suggests higher first-pass 
elimination of C5 and that other route of delivery should be considered for C5, like subcutaneous 
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delivery. This idea is supported in Witt-Enderby (US Patent 8,785,501) where C5, given 
subcutaneously at a dose of 200µg/kg body weight, was sufficient to produce uterine protection 
and modulate estrogen/ER-dependent progesterone receptor mRNA expression in the mammary 
gland ((P.A. Witt-Enderby et al., 2014); US Patent 8,785,501). These data suggest that C5 is 
bioavailable and has the potential to protect against the adverse effects associated with chronic 
tamoxifen usage on the uterus. 
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Chapter 6: Strengths and Limitations 
Melatonin-tamoxifen drug conjugates demonstrated context-specific activities, which depend 
on the receptor status, drug concentration, treatment duration, and/or linker length. However, 
several research questions still need to be answered and further experiments are required. 
i. The effect of drug conjugates, C4 and C5, on tumor growth and metastases needs to be 
studied in vivo using a PDX mouse model. Utilizing PDX models in drug discovery 
research incorporates a translational approach to evaluate drug effects in the laboratory 
setting (Whittle et al., 2015; Byrne et al., 2017). While established cell line-based research 
provides important insights into drug effects on cancer cells and basic mechanisms of 
action, treating patient tumors in vivo facilitates the translation of these findings to clinical 
observation. Hence, future studies will be examining the in vivo actions of C4 and C5 in 
PDXs of TamR and TNBC  in mice. 
ii. The pharmacokinetic analyses conducted for this dissertation were preliminary where the 
experiment was conducted for 24 hr and a single mouse was used for each time point. 
Therefore, further pharmacokinetic assessments are required for dosing calculations. 
Similar to the pharmacokinetic analysis conducted in this study, more mice will be 
included with longer time points in future studies. Since the observed plasma 
concentrations were very close to the limit of quantification, a higher dosage of C4, C5, 
and tamoxifen will also be tested in future studies. 
iii. More elaborate time-courses on C4 and C5 need to be conducted to assess the effect of 
chronic exposure on BC cell viability and migration. All the cell viability and cell 
migration assays were conducted over 24 hr. Hence, 48 and 72 hr of treatment duration 
will be used for cell viability assay (R. I. Sharma et al., 2011). Furthermore, Boyden 
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chamber assays will be used for a better assessment of C4- and C5-mediated actions on 
BC cell invasion and treatments will occur over longer periods of time (i.e., 24 and 48 hr) 
to confirm the outcomes of scratch/wound healing assay observed in this study. 
iv. Further analysis of the downstream targets modulated by C4 and C5 need to be assessed. 
Due to the limitation of the western blot method, regulation of 6 proteins (pERK1/2, 
pERK5, pAKT, NF-кB, RUNX2, and β1-INTEGRIN) by C4 and C5 were analyzed in 
this dissertation. RNA sequencing, which demonstrates a broad quantification of 
transcriptomes compared to western blot method (Brueffer et al., 2018) has been 
conducted on TU-BcX-4QAN TNBC tumor tissue exposed to C4 and C5 to identify as 
yet unknown downstream molecular targets modulated by these drug conjugates. 
v. Tamoxifen is a pro-drug that cannot be converted into the active form (4-OH-tamoxifen) 
in vitro. Hence, it is postulated that melatonin-4-OH-tamoxifen drug conjugates will 
demonstrate a better effect to inhibit BC cell viability and migration. Currently, novel 
melatonin-4-OH-tamoxifen drug conjugates have been developed and are being tested on 
BC cells for assessment of their anti-cancer actions on cell viability and migration. 
vi. Radioligand binding data indicated that GPR30 may play a role in C5-mediated action. 
Studies suggest that GPR30 plays a crucial role in BC pathogenesis and drug resistance 
induction (Molina et al., 2017). Hence, further experiments need to be conducted to 
ascertain its role in melatonin-tamoxifen drug conjugates’ action. 
vii. One important question that needs to be answered is the role of the receptors in C4- or 
C5-mediated anti-BC action. Studies using melatonin receptor antagonists and/or ER 
receptor agonists will help to determine the role of melatonin and estrogen receptors in 
mediating these anti-BC actions of C4 and C5. In the future, C4 and C5 conjugates will 
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be tested in the presence or absence of luzindole/estrogen for the viability and migration 
assays. 
viii. Another important question is how the linked melatonin-tamoxifen conjugates are 
working as a pharmacophore and modulating two different receptors at the same time. Co-
immunofluorescence may help to answer that question in future studies. Colocalization of 
MTR and ER will suggest dimerization or coactivation of the receptors and can be used 
for further characterization of the receptors (Porzionato et al., 2018). 
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Chapter 7: Conclusion 
It was observed that the anti-cancer actions of C4 and C5 were “context-specific” 
dependent upon the BC phenotype (i.e., ER+, HER2+ or triple-negative), the linkers connecting 
melatonin to tamoxifen, the endpoints measured (i.e., viability or migration), and the inhibitors 
used in the analysis (i.e., PD98059, Bix02189, or pictilisib). Based on the study outcomes, it is 
proposed that melatonin-tamoxifen drug conjugates are targeting a novel pharmacophore between 
melatonin receptors located at the plasma membrane or mitochondrial membrane and estrogen 
receptors located in the plasma membrane or in the nucleus; and this pharmacophore formed 
between the melatonin and estrogen receptors causes a unique interaction with downstream 






Figure 22: Molecular targets for C4 and C5 and the kinase inhibitors at melatonin and 
estrogen receptors, MEK1/2, MEK5, and PI3K in MCF-7 (ER+), MMC (ER-/PR-/HER2+) 
and TNBC (ER-/PR-/HER2-) cell lines. The drug conjugates can bind to MT1R and genomic 
(ERs) or non-genomic (GPR30) to regulate MAPK and PI3K. MT1R and ER can regulate MAPK 
while GPR30 and HER2 receptors can regulate the PI3K pathway. 
The C4 and C5 conjugates may be working differently in the BC cells based on the 
expression of different melatonin or estrogen receptors (i.e., plasma membrane melatonin 
receptors vs mitochondrial melatonin receptors or nuclear estrogen receptors vs plasma membrane 
estrogen receptors, GPR30) in the various BC cells. Also, the fact that the melatonin-tamoxifen 
drug conjugates are linked suggests that the simultaneous activation of estrogen receptors 
(genomic or non-genomic) or melatonin receptors (plasma membrane or mitochondrial) also may 
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explain the pharmacological differences observed between the melatonin-tamoxifen conjugates 
(linked) and melatonin plus tamoxifen combination (unlinked). 
 
Figure 23: Overall and composite mechanisms of action proposed for C4 and C5 effects in 
MCF-7, MMC and TNBC cell lines. The arrow indicates a positive feed into the signaling 
cascade while a perpendicular line indicates a negative (inhibitory) feed into the signaling cascade.  
The line indicates the linkage between melatonin and tamoxifen drug conjugate.  The blue boxes 
indicate the proposed sequence of events that would occur following the binding of C4 or C5 to 
melatonin receptors at the plasma membrane and with genomic ERs.  The orange boxes indicate 
the proposed interactions of melatonin to melatonin receptors at plasma membranes with 
tamoxifen to GPR30 receptors at the plasma membrane;  melatonin at melatonin receptors 
expressed on the mitochondria and tamoxifen with GPR30 receptors at the plasma membrane or 
at the mitochondria (Suofu et al., 2017). 
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In conclusion, melatonin-tamoxifen drug conjugates exhibited anti-cancer actions against 
BC, including triple-negative and TamR. In the future, more comprehensive experiments including 
both in-vitro and in-vivo to overcome the limitations and to implement clinical testing. 
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Chapter 9: Appendices 
9.1. Copyright statements 
This dissertation contains verbatim language from the paper, Hasan et al., 2019 (M Hasan, 
MA Marzouk, S Adhikari, TD Wright, BP Miller, MD Matossian, S Elliott, M Wright, M Alzoubi, 
BM Collins-Burow, ME Burow, U Holzgrabe, DP Zlotos, RE Stratford, and PA Witt-Enderby 
(2019) Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-
Tamoxifen Drug Conjugates as Breast Cancer Drugs, Molecular Pharmacol, 96(2): 272-296; 
DOI:https://doi.org/10.1124/mol.119.116202), which is reprinted with permission of the 
American Society for Pharmacology and Experimental Therapeutics. All rights reserved. 
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. 
This dissertation contains language from the paper, Hasan et al., 2018 (Hasan M, Leak RK, 
Stratford RE, Zlotos DP, Witt-Enderby PA. Drug conjugates—an emerging approach to treat 
breast cancer. Pharmacol Res Perspect. 2018;e00417. https://doi.org/10.1002/prp2.417), which is 
an open-access article under the terms of the Creative Commons Attribution License, which 
permits use, distribution, and reproduction in any medium, provided the original work is properly 
cited. 
 
9.2. ER/ERE activation by estrogen in wildtype and TamR MCF-7 cells 
9.2.1. Methods 
9.2.1.1. ER-ERE Activation Analysis. ER transcription factor ELISA (TransAMTM; Catalog: 
41996; Active Motif, Carlsbad, CA) followed by Schild Plot analysis were conducted to assess the 
functional change of ERs expressed in wildtype (WT) and TamR MCF-7 cells. This was conducted 
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to identify a potential mechanism underlying the tamoxifen resistance in TamR MCF-7 cells. This 
ELISA measures the colorimetric values in response to ER/ERE complex activation in the nuclear 
extract of the cells. 
9.2.1.2. Schild Plot analysis: The antagonistic potency of ERs expressed in WT and TamR MCF-
7 cells was measured by Schild regression developed by Heinz Otto Schild. Log EC50 ratios were 
calculated from the EC50 values obtained from ELISA assay using the following formula, 
log EC50 of estrogen with 4 OH tamoxifen EC50 of estrogen only 1  
Log EC50 ratios were calculated for all 4-OH-tamoxifen concentrations and plotted against the log 
estrogen concentrations. A linear regression line was drawn from the values and the anti-log of X-
intercept (pA2 and Kb) values were calculated as described (Tallarida RJ, Raffa RB, McGonigle 
P (eds) (1988) Chapter 9: Radioligand Binding. In: Principles in general pharmacology, vol 9. 
Springer, New York.). 
In the ELISA experiment and for the Schild plot analysis, concentration-response curves for 
estrogen (10 fM-10 mM) were conducted in the presence of increasing concentrations of 4-OH-
tamoxifen (1 pM, 1 nM, 10 nM, and 100 nM) and assessed for their effects on ER-mediated 
activation of ERE in both WT MCF-7 and TamR MCF-7 cells. 
9.2.2. Results 
The EC50 values in the presence or absence of 4-OH-tamoxifen are reported in Table A. 
The potency (EC50 = 12 nM) of estrogen to activate ERE in TamR MCF-7 cells was similar to the 
potency (EC50 = 18.4 nM) in wildtype (WT) MCF-7 cells. However, the ability of the competitive 
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antagonist of ER, 4-OH-tamoxifen, to antagonize the effects of estrogen is different between WT 
MCF-7 cells compared to TamR MCF-7 cells (Figure A).  
Table A: EC50 values for estrogen-mediated ER/ERE complex activation 
Potency (EC50) of estrogen Wt MCF-7 TamR MCF-7 
Estrogen only 18.4 nM 12 nM 
Estrogen + 1 pM 4-OH-tamoxifen 51 nM 5 nM 
Estrogen + 1 nM 4-OH-tamoxifen 94 nM 2.6 nM 
Estrogen + 10 nM 4-OH-tamoxifen 0.15 nM 2.2 nM 
Estrogen + 100 nM 4-OH-tamoxifen 5.18 nM 59 nM 
 
 
Figure A: Estrogen mediated ER/ERE complex activation in the presence or absence of 
different concentrations of 4-OH-tamoxifen in WT (A) and TamR (B) MCF-7 cell lines. The 
highest response was considered as a maximum response. Other values were normalized by the 
maximum response. Each value represents the average value of duplicates. 
 
For the Schild Plot analysis, EC50 values were calculated for each curve run with estrogen alone 
or in combination with the different concentrations of 4-OH-tamoxifen. The data demonstrate that 
no convergence in the Schild plot analysis occurred for TamR MCF-7 cells, whereas KB and pA2 
value for wild type MCF-7 cells were able to be calculated and determined to be KB of 11.28 fM 
and a pA2 value of 13.9 (Figure B). 
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Figure B: Schild plot analysis of estrogen-mediated ER/ERE complex activation in Wt and 
TamR MCF-7 cells. Y-axis represents logarithmic values of the EC50 ratio between estrogen with 
4-OH-tamoxifen and estrogen alone subtracted by 1. 
9.2.3. Summary and Conclusion 
The potency (EC50) values for estrogen to activate ER/ERE complexes in WT and TamR 
MCF-7 cells were similar indicating that estrogen’s ability to activate ERs was not different 
between the cells and so the TamR observed was not due to receptor desensitization. However, 
when Schild Plot analysis was conducted using 4-OH-tamoxifen as the competitive antagonist, 
differences between cell lines were observed. Specifically, in WT MCF-7 cells, a KB value of 
11.28fM was obtained while no KB value could be calculated because no antagonism or rightward 
shift in estrogen-mediated ERE activation occurred in TamR MCF-7 cells. These findings may 
indicate that the ER/ERE complex is so tightly coupled in TamR MCF-7 cells resulting in 
constitutive activation of the ER/ERE complex in TamR MCF-7 cells that could not be turned off 
by an ER antagonist, 4-OH-tamoxifen. This, perhaps, may explain the greater rates of growth in 
TamR cells vs wildtype MCF-7 cells. 
y = 0.1232x + 1.7192
pKB (x-intercept) = -13.9497
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